

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16432 A2

(51) International Patent Classification⁷: C07K 14/705, 16/28, C12N 15/12, 15/11

(21) International Application Number: PCT/DK01/00550

(22) International Filing Date: 20 August 2001 (20.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2000 01259 25 August 2000 (25.08.2000) DK

(71) Applicants: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(72) Inventors: WAHL, Philip; Ved Andebakken 8, 4th, DK-2000 Frederiksberg (DK). VISSING, Henrik; Virumstræde 13A, DK-2830 Virum (DK). GRØNDAAHL, Christian; Irisvej 19, DK-3500 Værløse (DK).

(74) Common Representative: NOVO NORDISK A/S; Novo Allé, DK-2880 Bagsværd (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SAM



(57) Abstract: Two receptors of meiosis activating sterols designated SAM1a and SAM1b have been identified.

Displacement of ³H-labelled
FF-MAS from SAM1b

WO 02/16432 A2

FIELD OF THIS INVENTION

5 The present invention relates to receptors or signalling proteins of FF-MAS, polynucleotides coding for receptors or signalling proteins of FF-MAS, probes hybridising with nucleic acids encoding receptors or signalling proteins of FF-MAS, DNA constructs comprising a sequence encoding receptors or signalling proteins of FF-MAS, culture cell lines wherein the DNA sequence encodes receptors or signalling proteins of FF-MAS, antibodies specifically 10 binding to receptors or signalling proteins of FF-MAS, hybridoma producing monoclonal antibodies specifically binding to receptors or signalling proteins of FF-MAS, and methods for detecting the presence of a compound having affinity to receptors or signalling proteins of FF-MAS.

15 **BACKGROUND OF THIS INVENTION**

Since the first IVF pregnancy was delivered in 1978, this procedure has resulted in thousands of pregnancies and opened a vast new frontier of research and treatment for the infertile couples. Still, there is a significant need for improved infertility treatment modalities to-day. It is presumed that about one out of seven couples experience problems with sub fertility or infertility.

IVF of human oocytes has become commonly used for the treatment of female and male sub fertility. The standard IVF treatment includes a long phase of hormone stimulation of the 25 female patient. The aspirated oocyte is subsequently fertilised in vitro and cultured. Continuous efforts have been made to optimise and simplify this procedure. Nevertheless, the overall pregnancy rate cannot be increased significantly over about 20% with the current treatment modalities. In a large European survey of IVF patients, it was found that 7.2 oocytes out of 11.5 aspirated oocytes per patient had undergone resumption of meiosis immediately 30 before fertilisation, only 4.3 oocytes were fertilised and only 2.2 oocytes reached the 8-cell embryo stage after fertilisation and in vitro culture (ESHRE, Edinburgh, 1997).

Due to the very unpredictable quality of the state of the art embryos today, more than one embryo has to be transferred just to give a reasonable chance of success. Therefore, it is

common to transfer 2-3 embryos (up to 5 embryos in some countries), which carries the very large side effect of multiple pregnancies with great discomfort and risk to both patient and children. Moreover, it has been estimated that the increased health care expenses due to multiple birth (twins, triplets etc.) is exceeding the entire IVF expenses.

5

Hence, there are several disadvantages with the current treatment.

Furthermore, weight gain, bloating, nausea, vomiting, labile mood and other patient discomforts together with patient reluctance to inject themselves are reported as disadvantages.

10

It is known from WO 96/00235 that certain sterol derivatives can be used for regulating meiosis. An example of such a sterol is 4,4-dimethyl-5 α -cholesta-8,14,24-triene-3 β -ol (hereinafter designated FF-MAS).

15

Hence, at present, in vitro maturation in humans has proven highly unsuccessful despite substantial interest and clinical efforts.

One way of trying to find compounds which effectively regulate meiosis is the use of pertinent receptors.

20

Receptors are defined as proteinaceous macromolecules that perform a signal transducing function upon ligand binding. Many receptors are located on the outer cell membrane, others are located intracellularly. The substance which is bound by the receptor is called a ligand, a term which is definitionally meaningful only in terms of its counterpart receptor. The term

25

"ligand" does not imply any particular molecular size or other structural or compositional feature other than that the substance in question is capable of binding, cleaving or otherwise interacting with the receptor in such a way that the receptor conveys information about the presence of the ligand to a target molecule. Stated alternatively, not all substances capable of binding a receptor are ligands, but all ligands are capable of binding a receptor. Receptors

30

do not include such substances as immunoglobulins.

Receptors are believed to function by a process variously termed activation or signal transduction. A ligand binds to the ligand binding domain in such a way that the conformation of the receptor molecule changes. This conformational change, called activation, modifies the

effect of the receptor on cytoplasmic components. Among changes brought about by receptor activation are changes in or development of receptor enzymatic activity.

Signalling proteins such as cAMP, IP₃, kinases, and phosphatases are proteins ubiquitously found in all tissues. These proteins cascade by various pathways, the stimulus from ligand/receptor interaction down stream to cellular events, typically changing the enzymatic activity or functional state of effector molecules.

The pharmaceutical industry in recent years has oriented its research to focus on the role of receptors in disease or injury and to design drugs, generally low molecular weight substances, that are capable of binding to the receptors. Drugs identified in this initial screen are then tested for the activity in vivo or in tissue explants. As a result, conventional techniques do not lend themselves to large-scale screening. Tissue samples or isolated cells containing the target receptors, for example ovarian tissue, are costly to obtain, present in limited quantity, and difficult to maintain in a functionally viable state. Additionally, it is often difficult to reliably and reproducibly administer the candidate drug to tissue samples. Screening assays using primary explants in tissue culture are undertaken in larger scale than is possible with tissue samples. However, it is more difficult to assay physiological effect and the assays are subject to interference from many sources, for example culture media or cultivation conditions. Finally, assays using receptors isolated from natural materials have the disadvantage that the receptor is subject to natural variability and suitable natural sources may not always be available. It is an object herein to provide readily reproducible, simple assay systems that can be practiced on a large scale for determining not only ligand binding but also the character of the binding as agonistic or antagonistic.

Similarly, meaningful clinical diagnosis often depends upon the assay of biologically active ligand without interference from inactive forms of the ligand, for example, ligands that have been subject to enzymatic or other processes in the test subject that change or even eliminate the activity of the ligand. Immunoassay methods are widely used in determining ligands in test samples. However, it is often quite difficult to identify antibodies that are able to discriminate between the active and inactive forms of a ligand. Receptors have frequently been used in place of antibodies as analyte binding reagents. However, not all substances that bind to receptors are necessarily capable of inducing receptor activity, i.e., active biologically. It is an object herein to provide a method that will identify ligands in clinical test sam-

ples which are active in inducing or inhibiting signal transduction by their receptors.

Cytoplasmic proteins can act as receptors or signalling molecules in cascading the stimulus from the ligand to cellular events. Various receptors or signalling protein types make use of
5 different pathways (for example small G proteins, calcium fluxes, phosphatases, and lipases), all of them resulting in changes of enzymatic activity or gene transcription.

Meiotic activating sterols (hereinafter designated MAS) constitute active signalling molecules first identified in follicular fluid and in bull testicular tissue. The sterols are described by By-
10 skov 1995 and Grøndahl et al. (*Biol. Reprod.* 58 (1998), 1297 *et seq.*) and in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically in Claim 1 thereof, as being potent activators of the meiotic process. No receptors or signalling proteins have been described to directly or indirectly signalling the meiotic effect of MAS sterols. Before this invention, the presence of the nature of a putative MAS receptor protein or a signalling protein has not previously been identified, although its presence has been suggested,
15 for example, by Grøndahl et al. (*Biol. Reprod.* 62 (2000), 775 *et seq.*).

On 29 September 2000, the nucleotide and amino acid sequence of clone NT2RM2001632 was released with accession number AK022554 and on 10 May 2001, the nucleotide and
20 amino acid sequence of clone NT2RP2000448 was submitted with accession number AK027535. No utility or action was mentioned for these clones.

There remains considerable need for an isolated and purified MAS receptor or a MAS signalling protein, as well as systems capable of expressing a MAS receptor or a MAS signalling
25 protein separate from other receptors. Further, it would be desirable to specifically identify the presence of a MAS receptor or a MAS signalling protein in cells and tissues, thereby avoiding the time-consuming, complex and non-specific functional pharmacological assays. It would also be desirable to screen and develop new agonists and/or antagonists specific for a MAS receptor or a MAS signalling protein for the use of antiinfertility or contraception
30 drugs, but to date this has not been possible. Quite surprisingly, the present invention fulfils these and other related needs.

SUMMARY OF THE INVENTION

Now, the present invention provides the nucleotide sequence of the receptors or signalling proteins of meiotic acting sterols (MAS). The present invention provides isolated and substantially pure MAS receptors or MAS signalling proteins and fragments thereof. These receptors or signalling proteins have been shown to be involved in the gamete maturation process induced by 3β -hydroxy-4,4-dimethylcholest-8,14,24-triene (hereinafter designated FF-MAS), specifically inducing, upon ligand activation, germinal vesicle breakdown (hereinafter designated GVB) in mouse oocyte cultured in vitro. Hence, a MAS receptor or a MAS signalling protein is defined as a proteinaceous macromolecule that perform a signal transducing function upon binding to FF-MAS. Briefly, a MAS receptor or a MAS signalling protein binds to FF-MAS. Alternatively, a MAS signalling protein can be designated a MAS binding protein.

A MAS receptor is any protein related to the protein SAM1a or SAM1b that possess the same functional characteristic regarding the interaction with FF-MAS or other endogenous meiosis activating sterols, for example, 3β -hydroxycholest-8,14-diene; 3β -hydroxy-4,4-dimethylcholest-8,24-diene; and 3β -hydroxycholest-8,24-diene, or their metabolites (as ligand). Functional characteristics include binding, receptor activation, and subsequent germinal vesicles breakdown (GVB) in oocytes. The amino acid sequence of SAM1a and SAM1b is stated in SEQ ID NO: 2 and SEQ ID NO: 4, below.

The MAS receptor can be used to discover profertility and antifertility compounds which can be used to men and women.

Having provided such receptors or signalling proteins in isolated or purified form, the invention also provides antibodies to the MAS receptor or signalling protein, in the form of antisera and/or monoclonal antibodies.

In another aspect, the invention provides the ability to produce the MAS receptor or MAS signalling protein and polypeptides or fragments thereof by recombinant means. The expressed MAS receptor or signalling protein or fragments may or may not have the biological activity of native receptor or signalling protein. Accordingly, isolated and purified polynucleotides are described which code for the receptor or signalling protein and fragment thereof, where the polynucleotides may be in the form of DNA, such as cDNA, or RNA. Based on

these sequences, probes may be used to hybridise and identify these and related genes which encode MAS receptors or MAS signalling proteins. The probes may be full length cDNA or as small as from 14 to 25 nucleotide, more often though from about 40 to about 50 or more nucleotides.

5

In related embodiments, the invention concerns DNA constructs which comprise a transcriptional promoter, a DNA sequence which encodes the receptor or signalling protein or fragment, and a transcriptional terminator, each operably linked for expression of the receptor or signalling protein. For expression, the construct may also contain at least one signal sequence. Further, for large-scale production, the expressed receptor or signalling protein may 10 also be isolated from the cells by, for example, immunoaffinity purification.

Cells or bacteria which express the MAS receptor or MAS signalling proteins may also be used to identify compounds which can alter the receptor or signalling protein-mediated metabolism of a cell. Compounds may be screened for binding to the receptor or signalling protein, and/or for effecting a change in receptor or signalling protein-mediated metabolism in 15 the host cell. Agonists and/or antagonists of the MAS receptor or MAS signalling proteins may also be screened in cell-free systems using purified receptor or signalling proteins or binding fragments thereof for the effect on ligand/receptor interaction or ligand/signalling 20 protein interaction, or using reconstituted systems such as micelles which also provide the ability to assess metabolic changes.

In yet other embodiments, the invention relates to methods for diagnosis, where the presence of a mammalian MAS receptor or MAS signalling protein in a biological sample may be 25 determined. For example, a monospecific antibody which specifically binds the receptor or signalling protein is incubated with the sample under conditions conducive to immune complex formation, which complexes are then detected, typically by means of a label such as an enzyme, fluorophore, radionuclide, chemiluminiscer, particle, or a second labelled antibody. Thus, means are provided for immunohistochemical staining of tissues, including ovarian or 30 testicular tissues, for the subject receptor or signalling proteins.

Based upon the similarity in sequence and the shared presence of a sterol binding domain at the protein level, the receptor proteins or signalling proteins of this invention can be said to belong to a novel super family of oxysterol binding proteins (hereinafter designated OSPB)

recently published in *J.Lipid.Res.* **40** (1999), 2204. No function whatsoever in gamete maturation of either gender or regulation of any meiotic processes has been assigned to this OSPB family.

5

BRIEF DESCRIPTION OF THE FIGURES

SEQ ID NO: 1 and SEQ ID NO: 3 are the nucleotides of the cDNA from two mouse MAS receptors or signalling peptides, designated SAM1a and SAM 1b, respectively, and having the 10 amino acid sequences stated in SEQ ID NO: 2 and SEQ ID NO: 4, respectively. SEQ ID NO: 5 and SEQ ID NO: 7 are the nucleotides of the cDNA from two human MAS receptors or signalling peptides, designated SAM1a and SAM 1b, respectively, and having the amino acid sequences stated in SEQ ID NO: 6 and SEQ ID NO: 8, respectively. SEQ ID NO: 9 through 14 are the nucleotides referred to in example 5.

15

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention presents the means to identify agonists, and antagonists of the MAS 20 receptor/ligand interaction or MAS signalling protein/ligand interaction by providing isolated MAS receptor or MAS signalling protein. The term "MAS receptor" refers to any proteins either derived from a naturally occurring MAS receptor, or which shares significant structural and functional characteristics peculiar to a naturally occurring MAS receptor. Such a receptor may result when regions of a naturally occurring receptor are deleted or replaced in such a 25 manner as to yield a protein having a similar function. Homologous sequences, allelic variations, and natural mutants; induced point, deletion, and insertion mutants; alternatively expressed variants; proteins encoded by DNA which hybridise under high or low stringency conditions to nucleic acids which encode naturally occurring MAS receptor; proteins retrieved from naturally occurring materials; and closely related proteins retrieved by antisera directed 30 against MAS receptor proteins are also included. Similarly, this applies to MAS signalling proteins.

By MAS receptor "ligand" is meant a molecule capable of being bound by the ligand-binding domain of MAS receptor, a MAS receptor analogue, or chimeric MAS receptor as generally

described in US Patent specification No. 4,859,609, incorporated by reference herein. The molecule may be chemically synthesised or may occur in nature. Ligands may be grouped into agonists and antagonists. Agonists are those molecules whose binding to a receptor induces the response pathway within a cell. Antagonists are those molecules whose binding to 5 a receptor blocks the response pathway within a cell.

By "isolated" MAS receptor or MAS signalling protein is meant to refer to MAS receptor or MAS signalling protein which is in other than its native environment such as a mammalian oocyte, including, for example, substantially pure MAS receptor as defined herein below.

10 More generally, isolated is meant to include MAS receptor or MAS signalling protein as a heterologous component of a cell or other system. For example, MAS receptor or MAS signalling protein may be expressed by a cell transfected with a DNA construct which encodes MAS receptor or MAS signalling protein, separated from the cell and added to micelles which contain other selected receptor or signalling proteins. In some instances, the term MAS receptor covers both a MAS receptor and a MAS signalling protein.

15

By purified MAS receptor or MAS signalling protein is meant MAS receptor or MAS signalling protein having a purity of at least 50%, preferably at least 80%, more preferred at least 90% (w/w).

20 Human SAM1a and SAM 1b are the clones NT2RP2000448 and NT2RM2001632, respectively.

A similar way of defining the MAS receptors or MAS signalling proteins of the present invention is the similarity between the amino acid sequence of the various MAS receptors or MAS 25 signalling proteins is at least about 90%, preferably about 95%, when compared with the amino acid sequence in SEQ ID NO: 2. Another expression of amino acid sequence similarity is homology. At the nucleotide level, the similarity between the nucleotides of the various MAS receptors or MAS signalling proteins is at least about 80%, preferably about 90%, when 30 compared with the nucleotides in SEQ ID NO: 1.

One way of determining the affinity constant of a MAS receptor or a MAS signalling protein is by the test described in example 3, below. One way of determining whether FF-MAS binds to a specific MAS receptor is by the test described in example 4, below. The test described in

example 3 below can be used to determine whether a specific protein is a MAS receptor or a MAS signalling protein or, in other words, whether a specific protein is an analogue of SAM1a as specified in the claims below. In the present context, the term "analogue" is intended to indicate a naturally occurring variant (including one expressed in other animal species, for example, human, monkey, mouse or rat) of the MAS receptor or a "derivative", i.e., a polypeptide which is derived from the native MAS receptor by suitably modifying the DNA sequence coding for the variant, resulting in the addition of one or more amino acids at either or both the C- and N-terminal ends of the native amino acid sequence, substitution of one or more amino acids at one or more sites in the native amino acid sequence, deletion of one or more amino acids at either or both ends of the native sequence or at one or more sites within the native sequence, or insertion of one or more amino acids in the native sequence.

In another aspect, the invention provides means for regulating the MAS receptor/ligand interaction or MAS signalling protein/ligand interaction, and thus treating, therapeutically and/or prophylactically, a disorder which can be linked directly or indirectly to MAS receptor or MAS signalling protein or to its ligands, such as FF-MAS. By virtue of having the receptor or signalling protein of the invention, agonists or antagonists may be identified which stimulate or inhibit, respectively, the interaction of ligand with MAS receptor or with MAS signalling protein. With either agonists or antagonists, the metabolism and reactivity of cells which express the receptor or signalling protein are controlled, thereby providing a means to control meiosis in order to treat infertility or to achieve a novel principle of contraception.

Thus, the invention provides screening procedures for identifying agonists or antagonists of events mediated by the ligand/MAS receptor or ligand/MAS signalling protein interaction. Such screening assays may employ a wide variety of formats, depending to some extent on which aspect of the ligand, receptor or signalling protein interaction is targeted. For example, such assays may be designed to identify compounds which bind to the receptor or signalling protein and thereby block or inhibit interaction of the receptor or signalling protein and thereby block or inhibit interaction of the receptor or signalling protein with the ligand. Other assays can be designed to identify compounds which can substitute for ligand and therefore stimulate MAS receptor-mediated or MAS signalling protein-mediated intracellular pathways. Yet other assays can be used to identify compounds which inhibit or facilitate the association of MAS receptor or MAS signalling protein to FF-MAS and thereby mediate the cellular response to MAS receptor or MAS signalling protein ligand.

In one functional screening assay, the initiation of fertilisation activation events are monitored in eggs which have been injected with, for example, mRNA which codes for MAS receptor or MAS signalling protein and subsequently exposed to selected compounds which
5 are being screened, in conjunction with or apart from an appropriate ligand. See generally, Kline *et al.*, *Science* 241 (1988), 464-467, incorporated herein by reference.

The screening procedure can be used to identify reagents such as antibodies which specifically bind to the receptor or signalling protein and substantially affect its interaction with
10 ligand, for example. The antibodies may be monoclonal or polyclonal, in the form of antiserum or monospecific antibodies, such as purified antiserum or monoclonal antibodies or mixtures thereof. For administration to humans, for example, as a component of a composition for in vivo diagnosis or imaging, the antibodies are preferably substantially human to minimise immunogenicity and are in substantially pure form. By substantially human is meant
15 generally containing at least about 70% human antibody sequence, preferably at least about 80% human, and most preferably at least about 90-95% or more of a human antibody sequence to minimise immunogenicity in humans.

Antibodies which bind to a MAS receptor or a MAS signalling protein may be produced by a
20 variety of means. The production of non-human antisera or monoclonal antibodies, for example, murine, lagomorpha equine, etc. is well known and may be accomplished by, for example, immunising the animal with the receptor or signalling protein molecule or a preparation containing a desired portion of the receptor or signalling protein molecule, such as that domain or domains which contributes to ligand binding. For the production of monoclonal
25 antibodies, antibody-producing cells obtained from immunised animals are immortalised and screened, or screened first for the production of antibody which binds to the receptor or signalling protein and then immortalised. As the generation of human monoclonal antibodies to human MAS receptor or MAS signalling protein antigen may be difficult with conventional techniques, it may be desirable to transfer antigen binding regions of the non-human antibodies, for example, the F(ab')₂ or hypervariable regions, to human constant regions (Fc) or framework regions by recombinant DNA techniques to produce substantially human molecules. Such methods are generally known in the art and are described in, for example, US
30 patent specification No. 4,816,397, and EP publications 173,494 and 239,400, which are incorporated herein by reference. Alternatively, one may isolate DNA sequences which code

for a human monoclonal antibody or portions thereof that specifically bind to the human receptor or signalling protein by screening a DNA library from human B cells according to the general protocol outlined by Huse et al., *Science* 246 (1989), 1275-1281, incorporated herein by reference, and then cloning and amplifying the sequences which encode the antibody (or binding fragment) of the desired specificity.

In other embodiments, the invention provides screening assays conducted in vitro with cells which express the receptor or signalling protein. For example, the DNA which encodes the receptor or signalling protein or selected portions thereof may be transfected into an established cell line, for example, a mammalian cell line such as BHK and CHO, using procedures known in the art (see, for example, Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, which is incorporated herein by reference). The receptor or signalling protein is then expressed by the cultured cells, and selected agents are screened for the desired effect on the cell, separately or in conjunction with an appropriate ligand such as FF-MAS or other MAS compounds. Means for amplifying nucleic acid sequences which may be employed to amplify sequences encoding the receptor or signalling protein or portions thereof are described in US patent specification Nos. 4,683,195 and 4,683,202, incorporated herein by reference.

In yet another aspect, the screening assays provided by the invention relate to transgenic mammals whose germ cells and somatic cells contain a nucleotide sequence encoding MAS receptor protein or signalling protein or a selected portion of the receptor or signalling protein which, for example, binds ligand. In yet a further aspect, the screening assays provided by the invention relate to transgenic mammals where the nucleotide sequence encoding a MAS receptor or a MAS signalling protein is molecularly targeted to produce knock out animals with the phenotypical loss of the specific MAS signalling function. Preferentially, the molecular knock out is tissue specific to gonadal tissue (ovary or testes) and is timely controlled in the development, thus inducible. There are several means by which a sequence encoding, for example, the human MAS receptor may be introduced into a non-human mammalian embryo or, alternatively, knocked out, some of which are described in, for example, US patent specification No. 4,736,866, Jaenisch, *Science* 240: 1468-1474 (1988) and Westphal et al., *Annu. Rev. Cell Biol.* 5: 181-196 (1989), which are incorporated herein by reference. The animal's cells then express the receptor or signalling protein and thus may be used as a convenient model for testing or screening selected agonists or antagonists.

In another aspect the invention concerns diagnostic methods and compositions. By means of having the MAS receptor or MAS signalling protein molecule and antibodies thereto, a variety of diagnostic assays are provided. For example, with antibodies, including monoclonal 5 antibodies, to MAS receptor or MAS signalling protein, the presence and/or concentration of receptor or signalling protein in selected cells or tissues in an individual or culture of interest may be determined. These assays can be used in the diagnosis and/or treatment of diseases such as, for example, male infertility, female infertility, or by means of contraception in both gender.

10 Numerous types of immunoassays are available and are known to those skilled in the art, for example, competitive assays, sandwich assays, and the like, as generally described in, for example US Patent specification Nos. 4,642,285; 4,376,110; 4,016,043; 3,879,262; 3,852,157; 3,850,752; 3,839,153; 3,791,932; and Harlow and Lane, *Antibodies, A Laboratory* 15 *Manual*, Cold Spring Harbor Publications, N.Y. (1988), each incorporated by reference herein. In one assay format, MAS receptor or MAS signalling protein is identified and/or quantified by using labelled antibodies, preferably monoclonal antibodies which are reacted with brain tissues, for example, ovarian or testicular tissue, oocyte preparations, or semen samples, and determining the specific binding thereto, the assay typically being performed 20 under conditions conducive to immune complex formation. Unlabelled primary antibody can be used in combination with labels that are reactive with primary antibody to detect the receptor or signalling protein. For example, the primary antibody may be detected indirectly by a labelled secondary antibody made to specifically detect the primary antibody. Alternatively, the anti-MAS receptor-antibody or MAS signalling protein-antibody can be directly labelled. A 25 wide variety of labels may be employed, such as radionuclides, particles (for example, gold, ferritin, magnetic particles, red blood cells), fluorophores, chemiluminescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, and ligands (particularly haptens).

The RNA encoding the MAS receptor MAS signalling protein may be directly detected in 30 cells with a labelled synthetic oligonucleotide probe targeting the MAS receptor RNA or MAS signalling protein RNA in a hybridisation procedure. Also, the polymerase chain reaction (Saiki et al., *Science* 239 (1988), 487, and US patent specification No. 4,683,195, each reference is hereby incorporated by reference) may be used to amplify DNA sequences, which are subsequently detected by their characteristic size on agarose gels, Southern blot of

these gels using MAS receptor DNA or MAS signalling protein DNA or a oligonucleotide probe, or a dot blot using similar probes. The probes may comprise from about 14 nucleotides to about 25 or more nucleotides, preferably, 40 to 60 nucleotides, and in some instances a substantial portion or even the entire cDNA of MAS receptor or MAS signalling

5 protein may be used. The probes are labelled with detectable signal, such as an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer, and paramagnetic particle. High stringency in connection with hybridisation is obtained using the proper temperature and salt concentration.

10 Kits can also be supplied for use with the receptor or signalling protein of the subject invention in the detection of the presence of the receptor or signalling protein or antibodies thereto, as might be desired in the case of autoimmune disease. Thus, antibodies to MAS receptor or MAS signalling protein, preferably monospecific antibodies such as monoclonal antibodies, or compositions of the receptor or signalling protein may be provided, usually in

15 lyophilised form in a container, either segregated or in conjunction with additional reagents, such as anti-antibodies, labels, gene probes, polymerase chain reaction primers and polymerase, and the like.

Even more specifically, the present invention relates to an isolated and/or purified polynucleotide molecule which hybridises at high stringency to an oligonucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which polynucleotide codes for a) a MAS receptor or for a MAS signalling protein; or b) a ligand binding domain of a MAS receptor or MAS signalling protein. This polynucleotide may be a RNA antisense sequence or a cDNA sequence. This polynucleotide may encode a polypeptide displaying MAS

25 receptor or MAS signalling protein activity. This polynucleotide may encode a MAS receptor or MAS signalling protein (being able to bind to FF-MAS) having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. The polynucleotide may have the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.

30 Furthermore, this invention relates to a probe of at least 12 nucleotides, said probe being capable of hybridising with nucleic acids which encode a MAS receptor or MAS signalling protein. This probe may comprise an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 capable of specifically hybridising with a gene which encodes a MAS receptor or MAS signalling protein, or allelic and species

variants thereof. This probe may comprise from about 40 to about 60 nucleotides in length.

This probe may be labelled to provide a detectable signal. This probe may comprise the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.

5 Furthermore, the present invention relates to a DNA construct comprising a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which encodes a) a MAS receptor or MAS signalling protein; or b) a ligand binding domain of a MAS receptor or MAS signalling protein. This DNA construct may have a DNA sequence encoding a MAS receptor
10 or MAS signalling protein having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

Furthermore, the present invention relates to a cultured cell line, yeast or bacteria transformed or transfected with a DNA construct which comprises a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which encodes a) a MAS receptor or MAS signalling protein; or b) a ligand binding domain or a transmembrane domain of a MAS receptor or MAS signalling protein. This cell line, yeast or bacteria may not express endogenous MAS receptor or MAS signalling proteins.

20 The MAS receptor or MAS signalling protein, a peptide fragment thereof or a salt thereof according to the present invention may be isolated and/or purified. The isolated and/or purified protein (MAS receptor or MAS signalling protein) may comprise the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

25 Furthermore, the present invention relates to an isolated antibody which specifically binds to a MAS receptor or MAS signalling protein. In this isolated antibody said antibody may be a monoclonal antibody. This isolated antibody may block the binding of MAS to a MAS receptor or MAS signalling protein.

30 Furthermore, the present invention relates to a hybridoma which produces a monoclonal antibody as mentioned herein.

Furthermore, the present invention relates to a method for detecting the presence of a compound or a salt thereof which has affinity for a MAS receptor or MAS signalling protein, comprising the steps of a) contacting the compound with the MAS receptor or MAS signalling protein, a peptide fragment thereof or a salt thereof; and b) measuring the affinity of said compound for the MAS receptor or MAS signalling protein. This method for detecting the presence of MAS antagonists, may comprise the steps of a) exposing a compound in the presence of a MAS agonist including MAS (FF-MAS) to a MAS receptor or MAS signalling protein coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor or MAS signalling protein and an associated response through the pathway; and b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor or MAS signalling protein , relative to the stimulation of the response pathway by the MAS agonist alone and there from determining the presence of a MAS antagonist. Furthermore, a method for detecting the presence of MAS agonists, may comprise the steps of a) exposing a compound in the presence of a MAS antagonist to a MAS receptor or MAS signalling protein coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor or MAS signalling protein and an associated response through the pathway; and b) detecting an increase of the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor or MAS signalling protein, relative to the stimulation of the response pathway by the MAS antagonist alone and there from determining the presence of a MAS agonist.

Furthermore, the present invention relates to a compound or a salt thereof which has affinity for the MAS receptor or a MAS signalling peptide and which compound or salt is detected by a method described herein.

Furthermore, the present invention relates to a method for producing a MAS receptor or MAS signalling protein having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which may comprise a) growing cells, yeast or bacteria transformed or transfected with a DNA construct which comprises a DNA sequence of SEQ ID NO: 1 or SEQ ID NO: 3 coding for the expression of the MAS receptor or MAS signalling protein, and b) isolating the MAS receptor or MAS signalling protein from the cells. In this method, the MAS receptor or MAS signalling protein may be isolated by immunoaffinity purification.

Furthermore, the present invention relates to a kit for screening a compound or a salt thereof which has affinity for a MAS receptor or MAS signalling protein, which contains the MAS receptor or MAS signalling protein, the peptide fragment thereof or a salt thereof.

- 5 Alternatively, the MAS receptor or MAS signalling protein may be defined as one which comprises the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signalling protein comprising the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM ,
- 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. Alternatively, the MAS receptor or MAS signalling protein may comprise the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signalling protein comprising the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with
- 15 an affinity constant below 100 μM , preferably below 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. Alternatively, the MAS receptor or MAS signalling protein may comprise the partial amino acid sequence shown in SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signalling protein comprising the partial amino acid sequence shown in
- 20 SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. Alternatively, the MAS receptor or MAS signalling protein may comprise the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM . The MAS receptor or MAS signal-
- 25 ling protein comprising the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 μM , preferably below 10 μM , may be different from the amino acid sequence in SEQ ID NO: 6 and 8. The MAS receptor or MAS signalling protein according to the present invention may be a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay.
- 30 The MAS receptor or MAS signalling protein being a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay, may be different from the amino acid sequence in SEQ ID NO: 6 and 8.

Furthermore, the present invention relates to a DNA construct which comprises a DNA sequence encoding a MAS receptor or MAS signalling protein as described herein or a DNA sequence coding for a functional analog thereof binding to FF-MAS. The DNA construct comprises a DNA sequence encoding a MAS receptor or MAS signalling protein as defined herein

5 or a DNA sequence coding for a functional analog thereof binding to FF-MAS may be different from the nucleotides of SEQ ID NO: 5 and 7. The DNA construct of the present invention may comprise the DNA sequence shown in SEQ ID NO: 1 or a fragment thereof, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M. This DNA construct comprising the DNA sequence

10 shown in SEQ ID NO: 1 or a fragment thereof, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, may be different from the nucleotides of SEQ ID NO: 5 and 7. The DNA construct according to the present invention may comprise the partial DNA sequence shown in SEQ ID NO: 5, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M.

15 This DNA construct comprising the partial DNA sequence shown in SEQ ID NO: 5, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 μ M, preferably below 10 μ M, may be different from the nucleotides of SEQ ID NO: 5 and 7.

20 Furthermore, the present invention relates to a recombinant expression vector which carries an inserted DNA construct according to any one of the preceding claims to a DNA construct.

Furthermore, the present invention relates to a cell containing a recombinant expression vector as defined herein. This cell may contain a DNA construct as defined herein integrated in its genome. This cell may be a eukaryotic cell, in particular an insect or a mammalian cell.

25

Furthermore, the present invention relates to a method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-MAS activity, the method comprising incubating a MAS receptor or MAS signalling protein as defined herein with a substance suspected to be an agonist or antagonist of FF-MAS, and subsequently with FF-MAS, or an analogue thereof, and detecting any effect of binding of FF-MAS, or the analogue to the MAS receptor or MAS signalling protein. Alternatively, the method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-MAS activity, may comprise incubating FF-MAS, or an analogue thereof with a substance suspected to be an agonist or antagonist of activity of FF-MAS, and

30

subsequently with a MAS receptor or MAS signalling protein as described herein, and detecting any effect of binding of FF-MAS, or the analogue to the receptor.

Furthermore, the present invention relates to the use of a MAS receptor or MAS signalling protein as defined herein for screening for agonists or antagonists of activity of FF-MAS.

Furthermore, the present invention relates to the use of DNA constructs as defined herein for isolation of tissue and/or organ specific variants of the MAS receptor or MAS signalling protein.

10

Furthermore, the present invention relates to the use of a MAS receptor or MAS signalling protein isolated as described herein.

The following examples are offered by way of illustration, not by limitation.

15

EXAMPLE 1

Microinjection of phosphorothionate oligonucleotides into mouse oocytes

20

Two antisense oligonucleotides (20 nucleotides) were utilized for microinjection: 5'-TCCAC-GATGGACGCCATCTT-3' and 5'-GCCAGCAGGAGAGCCATTG-3', complementary to the kozak sequence of the mRNA encoded by the cDNA sequence herein designated SAM1a and SAM1b, respectively, both of which are defined in SEQ ID NO: 1 and SEQ ID NO: 3, respectively, shown below. In control experiments, the corresponding sense oligonucleotides were microinjected: 5'-AAGATGGCGTCCATCGTGGA-3' and 5'-CGAATGGCTCTC-CTGCTGGC-3' for mRNA SAM1a and SAM1b, respectively. SAM1a antisense was co-injected with SAM1b antisense from a stock solution containing 1.25 µg/µl of each nucleotide in 10 % human serum albumin (hereinafter designated HSA) plus 5 mM Tris (pH value: 7.5). SAM1a sense was co-injected with SAM1b sense from a stock solution containing 1.25 µg/µl of each nucleotide in 10 % HSA plus 5 mM Tris (pH value: 7.5). Approximately 12 pg of each oligonucleotide (10 pL) were injected into the cytoplasm of individual germinal vesicle (GV)-stage oocytes loaded in a droplet of alpha-MEM supplemented with 0.8% HSA and 3 mM hypoxantine under mineral oil in a 35 mm petri dish on the stage of an inverted micro-

scope. The oocytes were obtained from the ovaries of 21-24 days old mice following 48 hours priming with follicle stimulating hormone (hereinafter designated FSH) as described by Grøndahl *et al.* 1998 in *Biol. Reprod.* **58** (1998), 1297 et seq. Oocytes were sucked on to a holding pipette (120 µM outer diameter and 20 µm inner diameter) and an injection pipette (Eppendorf, Hamburg, Germany) was fitted to a pressure microinjector (Eppendorf, Hamburg, Germany). The pipette holder was attached to a piezoelectric positioning system (Burleigh, NY, USA) mounted on a motorized micromanipulator (Luigs and Neumann, Ratingen, Germany). The injection pipette was pushed against the zona pelludica, and then a piezoelectric pulse was given, moving the injection pipette 20 µm forward. During this movement the pipette penetrated the zona pelludica and oolema and then a brief pressure pulse was applied to release a volume of approximately 10 µl into the oocytes cytoplasm. Injected oocytes were placed in a CO₂ incubator at 37°C for 20 hours before resumption of meiosis was triggered by addition of 10 µM FF-MAS to the hypoxanthine containing medium. The effect of FF-MAS was evaluated after 24 hours of further incubation as the number of oocytes in germinal vesicle breakdown (hereinafter designated GVBD). The rationale for the 20 hours cultivation period following injection of antisense oligonucleotides is to allow for degradation of mRNA coding for SAM1a and SAM1b protein. Consequently, when the level of MAS receptor protein or MAS signalling protein is reduced in the oocytes, the MAS response is blunted (from 100% to 50%, vide the table below).

20

Table 1

Oligonucleotide	GVBD/GVBD+GV 10 µM FF-MAS (24 hours)
SAM1a + SAM1b	13/25
Antisense	
SAM1a + SAM1b	10/10
Sense	
Non-injected oocytes	26/29

25

As shown in Table 1, GVBD was inhibited by 50% in antisense injected oocytes compared to control (i.e., sense injected and non-injected oocytes). This result indicates a selective inhibition of the mRNAs coding for SAM1a and SAM1b by the antisense probe. Furthermore, these results indicate that SAM1a and SAM1b proteins are crucial involved in the MAS sig-

nalling, since a functional knock out of *de novo* protein synthesis of these molecules partly disrupt the MAS signals in oocytes.

SAM1a and SAM1b are two closely related proteins originating from the same gene which
5 possesses complementary functions regarding MAS signalling in oocytes.

Example 2

10 FF-MAS binding assay:

10 µl of the unlabelled FF-MAS (1, 3, 10, 30, 100, 300, 1000, 3000 nM in 6.6% ethanol (EtOH)) was mixed with 10µl of 200 nM 3 H-labelled FF-MAS (approximately 12.8 Ci/mmol) in assay buffer (10 mM Tris; 1.5 mM EDTA; 10% glycerin; 1.0 mM 3-(3-cholamidopropyl)dimethylamino-1-propanesulphonate (hereinafter designated CHAPS, Boehringer Mannheim); 1% BSA (bovine serum albumin)). 10 µg of SAM1b protein freshly diluted in assay buffer, was added to give a final volume of 40 µl. Unspecific binding was measured in the presence of 30 µM unlabelled FF-MAS, total binding was determined by adding 10 µl assay buffer containing 6.6% EtOH. Incubation was performed for 2 hours at 4°C. 250 µl of ice-cold assay buffer containing 2% Cab-osil M-5 (silica gel from Fluka) and 0.2% dextran T70 (Sigma) was added to each tube, mixed and spinned briefly. Approximately 5 minutes after adding Cab-osil M-5, the tubes were centrifuged for 5 minutes, 14000 rpm (minifuge). 200µl of the supernatant was transferred to a microscint-tube and 3.5 ml atomlight (Packard) was added. Tubes were measured in a liquid scintillation counter. The results obtained are shown in Figure 1. "IC-50" is the concentration of unlabelled FF-MAS which displaces 50% of the bound 3 H FF-MAS.

Example 3

30

Assay to determine whether a specific polynucleotide encodes a protein which is a MAS receptor or a MAS signalling protein:

10 µl of the unlabelled FF-MAS (1, 3, 10, 30, 100, 300, 1000, 3000 nM in 6.6% EtOH) is mixed with 10 µl of 200 nM 3 H-labelled FF-MAS (approximately 12.8 Ci/mmol) in assay buffer (10 mM Tris; 1.5 mM EDTA; 10% glycerin; 1.0 mM CHAPS; 1% BSA). 10 µg of the specific protein to be tested freshly diluted in assay buffer, is added to give a final volume of 5 40 µl. Unspecific binding is measured in the presence of 30 µM unlabelled FF-MAS, total binding is determined by adding 10 µl assay buffer containing 6.6 % EtOH. Incubation is performed for 2 hours at 4°C. 250 µl of ice-cold assay buffer containing 2 % Cab-osil M-5 and 0.2 % dextran is added to each tube, mixed and spinned briefly. Approximately 5 minutes after adding Cab-osil M-5, the tubes are centrifuged for 5 minutes, 14000 rpm (minifuge).

10 200 µl of the supernatant is transferred to a microscint-tube and 3.5 ml atomlight is added. Tubes are measured in a liquid scintillation counter. If 3 H FF-MAS binding can be displaced by unlabelled FF-MAS, then the protein tested is a MAS receptor or a MAS signalling protein.

15 Example 4

Assay to determine whether a specific compound is a ligand:

10 µl of the compound to be tested (1, 3, 10, 30, 100, 300, 1000, 3000 nM in 6.6% EtOH) is 20 mixed with 10 µl of 200 nM 3 H-labelled FF-MAS (approximately 12.8 Ci/mmol) in assay buffer (10 mM Tris; 1.5 mM EDTA; 10% glycerin; 1.0 mM CHAPS; 1% BSA). 10 µg of SAM1a protein freshly diluted in assay buffer, is added to give a final volume of 40 µl. Un-specific binding is measured in the presence of 30 µM unlabelled FF-MAS, total binding is determined by adding 10 µl assay buffer containing 6.6% EtOH. Incubation is performed for 25 2 hours at 4°C. 250 µl of ice-cold assay buffer containing 2 % Cab-osil and 0.2% dextran is added to each tube, mixed and spinned briefly. Approximately 5 minutes after adding Cab-osil, the tubes are centrifuged for 5 minutes, 14000 rpm (minifuge). 200 µl of the supernatant is transferred to a microscint-tube and 3.5 ml atomlight is added. Tubes are measured in a liquid scintillation counter. If a compound can displace specific FF-MAS binding, then it is a 30 ligand to the MAS receptor or to a MAS signalling protein.

Example 5

Cloning of SAM1

An cDNA library was prepared from mRNA isolated from 10,000 oocytes, from 24 days old mice. The cDNA library was constructed in the pSPORT plasmid vector (LifeTechnologies).

5 Clones were picked at random and partially sequenced, and the sequences were assembled using phred/phrap programs. Out of several thousand clones that were sequenced, an assembly of two exhibited 21 % amino acids identity to a human Oxysterol Binding Protein.

The longest clone MOCY2864 was completely sequenced and no identical or orthologous genes were found in the databases. This new gene was named SAM1. Amplification of the 5'

10 end of SAM1 cDNA was performed by PCR on the oocyte library using a primer specific for pSPORT, #176959 (SEQ ID NO: 9) and a primer specific for SAM1 #198241 (SEQ ID NO: 10). This revealed cDNAs with two different 5' ends, which were designated SAM1a and SAM1b. Full-length PCR amplification was done on the mouse oocyte library using primer #199772 (SEQ ID NO: 11) and #198239 (SEQ ID NO: 12) for SAM1a and #201790 (SEQ ID

15 NO: 13) and #198239 (SEQ ID NO: 12) for SAM1b. Recognition sites for NheI and NotI, respectively, were incorporated in the primers. SAM1a and SAMb cDNAs were digested with NheI and NotI restriction enzymes and cloned into pcDNA3,1+ (Invitrogen).

DNA constructs directing the expression of SAM1a and SAM1b proteins fused to a C-terminal histidine stretch, which could be used for in purification because of its affinity to nickel-columns were made as follows. SAM1a and SAM1b cDNAs were PCR amplified using the primers #199772 (SEQ ID NO: 11) and #211465 (SEQ ID NO: 14) and primers #201790 (SEQ ID NO: 13) and #211465 (SEQ ID NO: 14), respectively. Recognition sites for NheI and XmaI, respectively, were incorporated in the primers. The PCR-products were then

20 cloned into pBlueBac4,5V5HIS (Invitrogen) using the restriction enzymes NheI and XmaI.

This intermediate construct was then digested by SmaI and BstBI, filled-in using the Klenow fragment of DNA polymerase1 and then religated. These construct were designated "SAM1a in pBlueBac4,5V5HIS" and "SAM1b in pBlueBac4,5V5HIS".

25

30

SAM1 expression in Sf9 cells

SAM1a-HIS and SAM1b-HIS proteins were expressed using recombinant Baculo virus in Sf9 cells according to the "Bac-N-Blue™ Transfection Kit" manual (Invitrogen).

To infect Sf9 insect cells 0,5 µg Bac-N-Blue™ DNA and the recombinant transfer plasmid "SAM1 in pBlueBac4,5V5HIS" (4 µg) were incubated with 1 ml Grace's Insect Media and 20 µl Insectin-Plus Liposomes for 15 minutes, then the mixture was added to 2×10^6 Sf9 cells in a 60 mm dish. The cells were left for 96 hours rocking at 27°C. Vira were isolated and plaque assay was performed. Putative recombinant plaques were picked and P-1 viral stocks were made. PCR analysis of recombinant viral clones was done and from positive clones high-titer viral stocks were then prepared. For large-scale SAM1a and SAM1b expression 500 ml Sf9 cells ($2,0 \times 10^6$ cells/ml) was infected with 25 ml virus ($1,8 \times 10^8$ plaque forming units/ml) or 60 ml virus (6×10^7 pfu/ml) for SAM1a and SAM1b, respectively. After 70 hours of incubation the cells were pelleted by centrifugation and the protein was purified.

SEQ ID NO: 9
15 CCAAGCTCTAATACGACTCAC

SEQ ID NO: 10
CTCAGCCACAAATGTTACAC

20 SEQ ID NO: 11
CTAGCTAGCACCATGGCGTCCATCGTGGAGG

SEQ ID NO: 12
ATAAGAATGCGGCCGCGAGGAGAAAAGGGAAGCGG
25

SEQ ID NO: 13
CTAGCTAGCACCATGGCTCTCCTGCTGGCCGCTTG

SEQ ID NO: 14
30 CCCGGGCATGCTTCACAGCACCAAGACGC

Example 6

Purification of SAM1a and SAM1b

Purification of HIS-SAM1a and HIS-SAM1b was performed according to the manual of QIAGEN: The QIAexpressionist forth edition.

5

Briefly, cell cultures of SF9 insect cells (containing the construct for 6xHis-SAM1a or 6xHis-SAM1b in a baculovirus expression vector) were centrifuged, pellets were lysed by addition of lysis buffer (50 mM NaH₂PO₄, 300 mM NaCl, 10 mM imidazole, pH 8) and lysozyme, sonication on ice 6 x 10 seconds, where after the lysates were cleared by centrifugation.

10 Cleared lysates were incubated under mild agitation with 50% slurry of Ni-NTA agarose (QIAGEN), for binding of 6xHis-SAM1a, washed twice (50 mM NaH₂PO₄, 300 mM NaCl, 20 mM imidazole, pH 8) and eluted with high concentration of imidazole (50 mM NaH₂PO₄, 300 mM NaCl , 250 mM imidazole, pH 8). Purified proteins were analysed on Coomassie (Brilliant Blue, Sigma) stained SDS-polyacrylamide gels (NuPAGE 4-12% Bis-Tris gel, Invitrogen) for evaluation of yield and purity.

15

SEQ ID NO: 1

SAM1a DNA

5 TTTGTTGT CATTGGCGGCTCCCAAGATGGCGTCCATCGTGGAAGGGCCGCTGAGCAAA
TGGACTAACGTGATGAAGGGATGGCAGTATCGTGGTCTGCTGGACTACAATGCAG
GGCTGCTCTCCTACTACACGTCCAAGGACAAAATGATGAGAGGCTCTGAAGAGGATG
CGTTAGACTCAGAGGGAGCTGTGATTGGTATAGACGACGAGGACAGCACCTCACA
ATCACTGTGATCAGAAAACCTCCACTCCAGGCTCGAGATGCAGACGAGCGAGAGA
10 AGTGGATCCATGCCTTAGAAGAAACTATTCTCGCCATACTCTTCAGCTTAAGGTTG
GATTCAAGGATTCATCCCCAGTGTCCAAGACTTGATAAGAAACTTACCGAGGCTGACGC
GTACCTGCAGATCTTGATAGAACAAATTAAAGCTTTGATGACAAGCTCAAAATTGAA
AGATGATGAACAGAGAAAGAAAGTTGAAACTCTCAAAGACACAAACAAATAGCATGGTAG
AATCAATTAAACACTGCATTGTGTTGCTACAGATTGCTAAAAGTACTATTAAATCCTGTA
15 ATGCAATATACCAGCCTAGTCCCTGGAACCTGTGATCAGCACAATGCCTCCCAGACT
GCCTTACCTCCAGAACCCGCTCAGTTGTGTAAGTCAGAGCAGCGTCCATCTCCTTAC
TGTTGGACCTGTGTTAGCTACCTGGGACATCATCAGACTCCAACACAAATAGTACAG
GCAGTGGGAACTCACCACCTAGCAGCAGTCTGACTCCTCCCAGCCATGTCAACTGTC
TCCAAATACAGTCCCAGAGTTCTTACTCTAGCAGTGAAGATGAGTTCTATGATGCTG
20 ATGAATTCCATCAAAGTGGCTCGTCCCCAAAGCGCTTAATAGATTCTCTGGATCTGCC
TCAGTCTTGACACACAGCAGCTCCGGAAATAGCTTAAACGCCAGATACCAACAGAGTC
TCTGAATTCCCATGTCCAATGGCACAAGCGATGCTGATCTTTGACTCACATGACG
ACAGAGATGATGATGGGGAGGCTGGGTAGTGGAGGAGCACAAGAGCGTTATCATGC
ACCTCTTATCACAAGTCAGGCTGGGATGGACCTCACAAAGGTAGTTCTTCAACGTT
25 ATTCTCGAGAGAAGATCTGTAGAAATGTATGCAGACTTTCCGCACATCCAGACCT
GTTCGTGAGCATTAGTGATCAGAAGGATCCCAGGGATCGAATGGTTAGGTTGTGAAA
TGGTACCTCTGGCCTTCCATGCAGGAAGGAGAGGATCGGTGGCCAAAAGCCGTACA
ATCCTATTTGGGTGAGATCTTCAGTGTCACTGGACGTTGCCAATGATACTGAAGAG
AACGCAGAGCTGTTCAGAAGGGCCGGTCCCTGGGTTCTAAGAACAGTGTAAACATT
30 TGTGGCTGAGCAAGTTCCCACCATCCGCCATTCACTGGACTAAATCAAATCCTGGGATGTCAA
TTGGGGTACACAACATAGGTCAAGGGCTGTGTCGTGCTGGAGTACGATGAGCACTA
CATCCTCACGTTCCCCAATGGCTATGGAAGGTCTATCCTGACAGTGCCTGGGTGGAA
TTGGGAGGAGAATGCAATATCAACTGCTCCAAAACGGGTTACAGCGCAAACATCGTCTT
35 CCACACTAAGCCTTCTATGGGGCAAGAACGACAGAATTACTGCAGAGATTTTCTC

CGAATGACAAGAAATCCTCTGCTCAATTGAAGGGGAATGGAATGGTATCATGTATGC
AAAATACGCAACAGGGAAAACACTGTCTTGAGACACCAAGAAATTGCCTATAATCA
AGAAAAAAGGTGAGGAAGTTGGAAGATCAGAATGAGTATGAGTCCCGCAGCCTTGGAA
GGATGTCACTTCAATTAAAAATCAGAGACATTGATGCAGCAACGGAAGCAAAGCACA
5 GACTTGAAGAAAGACAAAGAGCAGAACGCCAGAAAGGAAGGAGAAGGAAATTCACTG
GGAGACGAGGCTCTTCACGAGGATGGCGAATGCTGGGTTACGATGAGCCTTACTG
AAGCGTCTTGGTGCTGTGAAGCATTAGGCCACAACCGAGTCCACACCTGGTACCAG
GGCAGTAGGCCGTAAAGCAACAATCGATCTCCTCAGGAGAGCTTGTCACTCCTT
CTTAACGCAGTGGTCCATCTCAGGGATACTGGACTTGACGACACAGATGAACAATTA
10 AAGTGGAAACCGCTCCCTTTCTCCTCTGTGGCAGTTACAATTGACTTCAGGCCTG
AGAAAAAACTTCAGGTTCGAACATGACATCTCCTCTTCCAGATCCCAGTGGCTTGA
AAATATTATAGACAGTTCCAGGTCTCAGCTCCTGTCTAGTTCTGCTGTTGGC
ATAAAATCTTATCTCCAGTTCAATAATCTTGAGTTAGATAKACACACATGCGTAACA
GCTGACAGTTTCACAAGTACACCCACCTGTAAATACTGTAKCCTCAGTTAGAAAATT
15 AGTCATGTATGAAAATCAAGTGTAGGAAATTCTATGGTTCACCTATAACCTTATTTT
AGAATTGAACATATGATTAGATTGTATCTAACCTGAAGTATAATTATATGCAGTGCTTCTT
AAGGCTTCATAAAATAATTCCAACCTTTAAAAAAAAAAAAAA

SEQ ID NO: 2

SAM1a peptide

5 MASIVEGPLSKWTNVMKWQYRWFVLDYNAGLSYYTSKDMMRGSRRGCVRLRGAVIG
IDDEDDSTFTITVDQKTFHFQARDADEREKWIHALEETILRHTLQLQGLDSGFIPSVQDFDKK
LTEADAYLQILIEQLKLQFDKLQNCKDDEQRKKVETLKDTTNSMVESIKHCIVLLQIAKSTINPV
DAIQQPSPLEPVISTMPSQTALPPEPAQLCKSEQRPSSLPGPVLATLGHHQTPNNTGSG
NSPPSSSLTPPSHVNLSPNTVPEFSYSSSEDEFYDAEFHQSGSSPKRLIDSSGSASVLTHS
10 SSGNSLKRPDTTESLNSSMSNGTSDADLFDSHDDRDDDGEAGSVEEHKSVIMHLLSQVRL
GMDLTGVVLPFTFILERRSLLEMYADFFAHPDFVSISDQKDPRDRMVQVVKWYLSAFHAGR
RGSVAKKPYNPILGEIFQCHWTLNDTEENAELEVSEGPPVSKNSVTVAEQVSHHPPIS
AFYAECFNKKIQFNAHIWTKSKFLGMSIGVHNIGQGCVSCLEYDEHYILTFFNGYGRSILTV
WVELGGECHNINCSTGYSANIVHTKPFYGGKKHRITAEIFSPNDKKSFCISIEGEWNGIMYA
15 KYATGENTVFVDTKLPPIKKVKRKLEDQNEYESRSLWKDVTNLKIRDIDAATEAKHRLEER
QRAEARERKEIQQWETRLFHEDGECHVYDEPLLKRLGAVKH

SEQ ID NO: 3

SAM1b DNA

5 GGGCCCCCTCCCTGAGACGGCGGCCGCCGCGAATGGCTCCTGCTGGCCGC
TTGCGGAGGTTGGATTCAAGGATTCACTCCCCAGTGTCCAAGACTTGTATAAGAAACTTA
CCGAGGCTGACCGTACCTGCAGATCTTGATAGAACATTAAAGCTTTGATGACAAG
CTTCAAAATTGTAAGATGATGAACAGAGAAAGAGTTGAAACTCTCAAAGACACAACA
AATAGCATGGTAGAATCAATTAAACACTGCATTGTGTTGCTACAGATTGCTAAAAGTACT
10 ATTAATCCTGTAGATGCAATATACCAGCCTAGTCCCTGGAACCTGTGATCAGCACAAT
GCCTTCCCAGACTGCCTTACCTCCAGAACCCGCTCAGTTGTAAAGTCAGAGCAGCGT
CCATCTCCTTACCTGTTGGACCTGTGTTAGCTACCTGGGACATCATCAGACTCCAAC
ACCAAATAGTACAGGCAGTGGAACTCACCACCTAGCAGCAGTCTGACTCCTCCCAGC
CATGTCAACTTGTCTCCAATACAGTCCCAGAGTTCTTACTCTAGCAGTGAAGATGA
15 GTTCTATGATGCTGATGAATTCCATCAAAGTGGCTCGTCCCCAAAGCGCTTAATAGATT
CTTCTGGATCTGCCTCAGTCTTGACACACAGCAGCTCCGGAAATAGCTAAAACGCCA
GATACCACAGAGTCTCTGAATTCCATGTCCAATGGCACAGCGATGCTGATCTTT
TGACTCACATGACGACAGAGATGATGGGGAGGCTGGTCAGTGGAGGAGCACAA
GAGCGTTATCATGCACCTCTTATCACAAGTCAGGCTGGGATGGACCTCACAAAGGTA
20 GTTCTTCCAACGTTATTCTCGAGAGAAGATCTCTGTTAGAAATGTATGCAGACTTTTC
GCACATCCAGACCTGTTCGTGAGCATTAGTGATCAGAAGGATCCCAGGGATCGAATGG
TTCAGGTTGTGAAATGGTACCTCTCGGCTTCCATGCAGGAAGGAGAGGATCGTGGC
CAAAAAGCCGTACAATCCTATTTGGGTGAGATCTTCAGTGTCACTGGACGTTGCCGA
ATGATACTGAAGAGAACGCAGAGCTCGTTCAGAAGGGCCGGTCCCTGGGTTCTAA
25 GAACAGTGTAAACATTGGCTGAGCAAGTTCCCACCATCGCCCCATTCAGCCTTT
ATGCTGAGTGTAAACAAGAAGATACAATTCAATGCTCATCTGGACTAAATCAAAT
TCCTGGGATGTCAATTGGGTACACAACATAGGTCAAGGCTGTCTCGTGTCTGGA
GTACGATGAGCACTACATCCTCACGTTCCCACATGGCTATGGAAGGTCTATCCTGACAG
TGCCCTGGGTTGGAATTGGGAGGAGAACATGCAATATCAACTGCTCCAAAACGGGTTACAG
30 CGCAAACATCGTCTTCCACACTAAGCCTTCTATGGGGCAAGAACGACAGAATTACTG
CAGAGATTTCTCCGAATGACAAGAAATCCTCTGCTCAATTGAAGGGAAATGGAAT
GGTATCATGTATGAAAATACGCAACAGGGAAAACACTGTCTTGTAGACACCAAGAA
ATTGCCTATAATCAAGAAAAAGGTGAGGAAGTTGGAAGATCAGAATGAGTATGAGTCCC
GCAGCCTTGGAGGATGTCACTTCAATTAAAATCAGAGACATTGATGCAGCAACG
35 GAAGCAAAGCACAGACTTGAAGAAAGACAAAGAGCAGAAGCCGAGAAAGGAAGGAGA

AGGAAATTCA GTGGGAGAC GAGGCTTT CACGAGGA TGGCGA ATGCTGGTTACG
ATGAGCCTTACTGAAGCGTCTGGTGCTGTGAAGCATTAGGCCGACAACCGAGTCCA
CACCTGGTGACCAGGGCAGTAGGC GTAATTAGCAACAATCGATCTTCCTTCAGGAGA
GCTTGTCACTTCCTTCTTAACGCAGTGGTTCTATCTCAGGGATACTGGACTTGACGAC
5 ACAGATGAACAATTAAAGTGGAAACCGCTTCCCTTTCTCCCTGTGGCAGTTACAATT
TGACTTCAGGCCTGAGAAAACCTTCAGGTTCGAAACATGACATCTTCCTTTCCAGA
TCCCATGCTTGAAAAATTTATAGACAGTCCAGGTCTCAGCTTCCTGTCCCTAGTT
CTGCTGTTGGGCATAAAATCTTATCTCCAGTTCATATAATCTTGAGTTAGATAKAC
ACACATGCGTAACAGCTGACAGTTTCACAAGTACACCCACCTGTAAATACTGTAKCCT
10 CAGTTAGAAAATTAGTCATGTATGAAAATCAAGTGTAGGAAATTCTGGTTCA
TATAACCTTATTTAGAATTGAACTATGATTAGATTGTATCTAACCTGAAGTATAATT
TATGCAGTGCTTCTTAAGGCTTCATAAAATAATTCTAACCTTTAAAAAAA
A

SEQ ID NO: 4

SAM1b peptide

5 MALLLAACGGLDSGFIPSVQDFDKKLTEADAYLQILIEQLKLFDDKLQNCKDDEQRKKVETLK
DTTNSMVESIKHCIVLLQIAKSTINPVDAIYQPSPLEPVISTMPSQTALPPEPAQLCKSEQRPS
SLPVGPVLATLGHHQTPTPNSTGSGNSPPSSLTPPSHVNLSPNTVPEFSYSSSEDEFYDA
DEFHQSGSSPKRLIDSSGSASVLTHSSSGNSLKRPDTTESLNSSMSNGTSADLFDSHDDR
DDDGEAGSVEEHKSIVMHLLSQVRLGMDLTkvVLPTFILERRSLLEMYADFFAHPDFLVSI
10 QKDPRDRMVQVVKWYLSAFHAGRRGSVAKKPYNPILGEIFQCHWTLPNDEENAEVSEG
PVPWVKNSVTVAEQVSHHPPISAFYAECFNKKIQFNAHIWTKSKFLGMSIGVHNIGQGCV
SCLEYDEHYILTFFPNGYGRSILTVPWVELGGECNINCSTGYSANIVFHTKPFYGGKKHRITA
EIFSPNDKKSFCsieGEWNGIMYAKYATGENTVFVDTKLPIIKKKVRKLEDQNEYESRSLWK
DVTFLNKIRDIDAATEAKHRLEERQRAEARERKEKEIQWETRLFHEDGEWCWVYDEPLLKRL
15 GAVKH

20

25

What is claimed is:

1. An isolated and/or purified polynucleotide molecule which hybridises at high stringency to an oligonucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 5 and which polynucleotide codes for a) a MAS receptor (i.e. a protein having ability to bind to 3 β -hydroxy-4,4-dimethylcholest-8,14,24-triene (herein designated FF-MAS)) or for a MAS signalling protein (i.e. a protein having ability to bind to FF-MAS); or b) a ligand binding domain of a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
10
2. The polynucleotide of the preceding claim, which is a RNA antisense sequence.
3. The polynucleotide of claim 1, which is a cDNA sequence.
- 15 4. The polynucleotide according to any one of the preceding claims, which encodes a polypeptide displaying MAS receptor (being able to bind to FF-MAS) or MAS signalling protein activity (being able to bind to FF-MAS).
5. The polynucleotide of claim 1, which encodes a MAS receptor (being able to bind to FF-
20 MAS) or MAS signalling protein (being able to bind to FF-MAS) having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
6. The polynucleotide according to any one of the preceding claims having the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.
25
7. A probe of at least 12 nucleotides, said probe being capable of hybridising with nucleic acids which encode a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
- 30 8. A probe, according to the preceding claim, which comprises an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 capable of specifically hybridising with a gene which encodes a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), or allelic and species variants thereof.

9. The probe of the preceding claim, which comprises from about 40 to about 60 nucleotides in length.
- 5 10. The probe according to any one of the two preceding claims, which is labelled to provide a detectable signal.
11. The probe according to any one of the two preceding claims comprising the nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3.
- 10 12. A DNA construct comprising a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which encodes a) a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS); or b) a ligand binding domain of a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
- 15 13. The DNA construct of the preceding claim, wherein the DNA sequence encodes a MAS receptor or MAS signalling protein having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
- 20 14. A cultured cell line, yeast or bacteria transformed or transfected with a DNA construct which comprises a DNA sequence which hybridises at high stringency to an oligonucleotide or polynucleotide of 25 or more contiguous nucleotides of SEQ ID NO: 1 or SEQ ID NO: 3 and which encodes a) a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS); or b) a ligand binding domain or a transmembrane domain of a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
- 25 15. The cell line, yeast or bacteria according to the preceding claim, which does not express endogenous MAS receptor (being able to bind to FF-MAS) or MAS signalling proteins (being able to bind to FF-MAS).

16. An MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), a peptide fragment thereof or a salt thereof, which is isolated and/or purified.
- 5 17. The isolated and/or purified protein of the preceding claim, comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 or a sequence of said amino acid sequence being able to bind to FF-MAS.
- 10 18. An isolated antibody which specifically binds to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
19. The isolated antibody of the preceding claim wherein said antibody is a monoclonal antibody.
- 15 20. The isolated antibody according to any one of the preceding two claims, which blocks the binding of MAS to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
21. A hybridoma which produces a monoclonal antibody according to any of the two preceding claims.
22. A method for detecting the presence of a compound or a salt thereof which has affinity for a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), comprising the steps of a) contacting the compound with the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), a peptide fragment thereof or a salt thereof; and b) measuring the affinity of said compound for the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS).
- 25 30 23. The method of the preceding claim for detecting the presence of MAS antagonists, comprising the steps of a) exposing a compound in the presence of a MAS agonist including MAS to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor (being able to

bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) and an associated response through the pathway; and b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS),
5 relative to the stimulation of the response pathway by the MAS agonist alone and there from determining the presence of a MAS antagonist.

24. The method of any one of the two preceding claims for detecting the presence of MAS agonists, comprising the steps of a) exposing a compound in the presence of a MAS antagonist to a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) coupled to a response pathway under conditions and for a time sufficient to allow binding of the compound to the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) and an associated response through the pathway; and b) detecting an increase of the stimulation of the response pathway resulting from the binding of the compound to the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), relative to the stimulation of the response pathway by the MAS antagonist alone and there from determining the presence of a MAS agonist.
10
15

20 25. A compound or a salt thereof which has affinity for the MAS receptor (being able to bind to FF-MAS) or a MAS signalling peptide (being able to bind to FF-MAS) and which compound or salt is detected by the method according to claim 20 or 21.

26. A method for producing a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, which comprises a) growing cells, yeast or bacteria transformed or transfected with a DNA construct which comprises a DNA sequence of SEQ ID NO: 1 or SEQ ID NO: 3 coding for the expression of the MAS receptor or MAS signalling protein, and b) isolating the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) from the cells.
25
30

27. The method according to the preceding claim, wherein the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS) is isolated by immunoaffinity purification.

28. A kit for screening a compound or a salt thereof which has affinity for a MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), which contains the MAS receptor (being able to bind to FF-MAS) or MAS signalling protein (being able to bind to FF-MAS), the peptide fragment thereof or a salt thereof.

5

29. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM.

10

30. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 2, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.

15

31. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM.

20

32. A MAS receptor, which comprises the amino acid sequence shown in SEQ ID NO: 4, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.

25

33. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM.

30

34. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 6, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.

35. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM.

5 36. A MAS receptor, which comprises the partial amino acid sequence shown in SEQ ID NO: 8, or an analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.

10 37. A MAS receptor according to any one of the preceding claims to a MAS receptor, which is a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay.

15 38. A MAS receptor according to any one of the preceding claims to a MAS receptor, which is a soluble and purified protein which is present in a buffer suitable for detecting ligands, for example by a binding assay, with the proviso that it is different from the amino acid sequence in SEQ ID NO: 6 and 8.

20 39. A DNA construct which comprises a DNA sequence encoding a MAS receptor according to any one of the preceding claims to a MAS receptor or a DNA sequence coding for a functional analog thereof (binding to FF-MAS).

25 40. A DNA construct which comprises a DNA sequence encoding a MAS receptor according to any one of the preceding claims to a MAS receptor or a DNA sequence coding for a functional analog thereof (binding to FF-MAS), with the proviso that it is different from the nucleotides of SEQ ID NO: 5 and 7.

30 41. A DNA construct comprising the DNA sequence shown in SEQ ID NO: 1 or a fragment thereof, or a DNA sequence coding for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM.

42. A DNA construct according to the previous claim, which comprises the DNA sequence shown in SEQ ID NO: 1 or a fragment thereof, or a DNA sequence coding for a functional

analogue thereof binding FF-MAS, with an affinity constant below 100 µM, preferably below 10 µM, with the proviso that it is different from the nucleotides of SEQ ID NO: 5 and 7.

43. A DNA construct according to any one of the preceding claims on a DNA construct, which
5 comprises the partial DNA sequence shown in SEQ ID NO: 5, or a DNA sequence coding
for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 µM,
preferably below 10 µM.
44. A DNA construct according to any one of the preceding claims on a DNA construct, which
10 comprises the partial DNA sequence shown in SEQ ID NO: 5, or a DNA sequence coding
for a functional analogue thereof binding FF-MAS, with an affinity constant below 100 µM,
preferably below 10 µM, with the proviso that it is different from the nucleotides of SEQ ID
NO: 5 and 7.
- 15 45. A recombinant expression vector which carries an inserted DNA construct according to
any one of the preceding claims to a DNA construct.
46. A cell containing a recombinant expression vector according to the preceding claim.
- 20 47. A cell containing a DNA construct according to any one of the preceding claims to a DNA
construct integrated in its genome.
48. A cell according to any one of the two preceding claims, which is a eukaryotic cell, in par-
ticular an insect or a mammalian cell.
- 25 49. A method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-
MAS activity, the method comprising incubating a MAS receptor according to any one of
the preceding claims to a MAS receptor with a substance suspected to be an agonist or an-
tagonist of FF-MAS, and subsequently with FF-MAS, or an analogue thereof, and detecting
30 any effect of binding of FF-MAS, or the analogue to the MAS receptor.
50. A method of screening for ligands to the MAS receptor, i.e., agonists or antagonists of FF-
MAS activity, the method comprising incubating FF-MAS, or an analogue thereof with a
substance suspected to be an agonist or antagonist of activity of FF-MAS, and subse-

quently with a MAS receptor according to any one of the preceding claims to a MAS receptor, and detecting any effect of binding of FF-MAS, or the analogue to the receptor.

51. Use of a MAS receptor according to any one of the preceding claims to a MAS receptor for screening for agonists or antagonist of activity of FF-MAS.
52. Use of DNA constructs according to any one of the preceding claims to a NDA construct for isolation of tissue and/or organ specific variants of the MAS receptor according to any one of the preceding claim to a MAS receptor.
- 10 53. Use of a receptor isolated according to the preceding claim for the screening of MAS agonists or antagonist.

NOVO NORDISK A/S & SCHERING AKTIENGESELLSCHAFT

1 / 1




Figure 1: Displacement of ³H-labelled FF-MAS from SAM1b

SEQUENCE LISTING

<110> NOVO NORDISK A/S

5 <120> SAM

<130> 6229.000-DK

<160> 4

10 <170> PatentIn version 3.0

<210> 1

<211> 2814

<212> DNA

15 <213> ARTIFICIAL SEQUENCE

<400> 1

tttgtgtca ttggcggctc ccaagatggc gtccatcgta gaaggcccgc tgagcaaatg 60

20 gactaacgtg atgaaggat ggcagtatcg ttggttcgta ctggactaca atgcagggt 120

gctctcctac tacacgtcca aggacaaaat gatgagaggc tctcgaagag gatgcgttag 180

25 actcagagga gctgtgattt gatatagacga cgaggacgac agcaccctca caatcactgt 240

cgatcagaaa accttccact tccaggctcg agatgcagac gagcggagaga agtggatcca 300

tgccttagaa gaaactattt ttcggccatac tcttcagctt caagggttgg attcaggatt 360

30 catccccagt gtccaaagact ttgataagaa acttaccgag gctgacgcgt acctgcagat 420

cttgatagaa caattaaagc ttttgatga caagcttcaa aattgtaaag atgatgaaca 480

gagaaagaaa gttgaaactc tcaaagacac aacaaatagc atggtagaat caattaaaca 540

35 ctgcattgtg ttgctacaga ttgctaaaag tactattaat cctgttagatg caatatacca 600

gccttagtccc ttggaacctg tgatcagcac aatgccttcc cagactgcct tacctccaga 660

40 acccgctcag ttgtgttaat cagagcagcg tccatcttcc ttacctgtt gacctgtgtt 720

agctaccttgg gacatcatc agactccaa accaaatagt acaggcagtg ggaactcacc 780

accttagcagc agtctgactc ctcccagcca tgtcaacttg tctccaaata cagtcggcaga 840

45 gttctttac tcttagcagtg aagatgagtt ctatgatgt gatgaattcc atcaaagtgg 900

ctcgccccca aagcgcttaa tagattcttcc tggatctgcc tcagtcgttga cacacagcag 960

50 ctccggaaat agcttaaaac gcccagatac cacagagtct ctgaattcct ccatgtccaa 1020

tggcacaagc gatgctgatc ttttgactc acatgacgac agagatgtat atggggaggc 1080

tgggtcagtg gaggagcaca agagcgatcatgcaccc tttatcacaag tcaggctggg 1140

55 gatggacctc acaaaggtag ttcttccaaat gtttattctc gagagaagat ctctgttaga 1200

aatgtatgca gacttttcg cacatccaga cctgttcgtg agcatttagt atcagaagga 1260

60 tcccaggat cgaatggttc aggttgtaa atggtacctc tcggccttcc atgcaggaag 1320

	gagaggatcg gtggccaaaa agccgtacaa tcctatttg ggtgagatct ttcagtgtca	1380
	ctggacgttgc cgaatgata ctgaagagaa cgcagagctc gtttcagaag ggccggttcc	1440
5	ctgggttct aagaacagtta acatattgt ggctgagcaa gtttcccacc atccgccccat	1500
	ttcagccctt tatgctgagt gtttaacaa gaagatacaa ttcaatgctc atatctggac	1560
10	taaatcaaaa ttccctggaa tgtcaattgg ggtacacaac ataggtcagg gctgtgtctc	1620
	gtgtctggag tacatgagc actacatcct cacgttcccc aatggctatg gaaggtctat	1680
	cctgacagtgc ccctgggtgg aattgggagg agaatgcaat atcaactgct ccaaaacggg	1740
15	ttacagcgca aacatcgctc tccacactaa gcctttctat gggggcaaga agcacagaat	1800
	tactgcagag atttttctc cgaatgacaa gaaatccttc tgctcaatttga aagggaaatg	1860
20	aatggtatac atgtatgcaaa atacgcaac agggaaaac actgttttg tagacaccaa	1920
	gaaattgcct ataatcaaga aaaaggtgag gaagttggaa gatcagaatg agtatgagtc	1980
	ccgcagcctt tggaaggatg tcactttcaa tttaaaaatc agagacatttgc atgcagcaac	2040
25	ggaagcaaaag cacagacttgc aagaaagaca aagagcagaa gcccgagaaa ggaaggagaa	2100
	ggaaatttcag tgggagacga ggcttttca cgaggatggc gaatgtggg ttacgtga	2160
30	gcctttaactg aagcgttttgc gtgtgtgaa gcattaggcc gacaaccgag tccacacctg	2220
	gtgaccagggg cagtaggcgt aattaagcaa caatcgatct tccttcagga gagcttgtca	2280
	cttccttctt aacgcgttgc ttccatctc agggatactg gacttgacga cacagatgaa	2340
35	caattaaagt ggaaaccgt tccctttct cctctgtggc agttacaatt ttgacttcag	2400
	gcctgagaaa aacttcaggt ttcaaacat gacatcttttccatgc atcccatgct	2460
40	ttgaaaaata ttatagaca gttccagggtc tcagttctt gtcctctatgt tctgtgttc	2520
	gggcataaaaa tctttatctc cagttcatat aatctttagt tttagataca cacatgcg	2580
	taacagctga cagttttca caagtacacc cacctgtaaa tactgtakcc tcagtttaga	2640
45	aaatttagtgc atgtatgaaa atcaagtgtt agggaaatttc atggtttcac ctataacctt	2700
	tatTTTAAAG ttgaactatg attagattgt atctaaacctt gaagtataat tatatgcagt	2760
	gcttcttaag gcttcataaa ataattttcc aacctttta aaaaaaaaaaaa aaaa	2814
50		

<210> 2
 <211> 723
 <212> PRT
 5 <213> ARTIFICIAL SEQUENCE
 <400> 2

10	Met Ala Ser Ile Val Glu Gly Pro Leu Ser Lys Trp Thr Asn Val Met	1	5	10	15
	Lys Gly Trp Gln Tyr Arg Trp Phe Val Leu Asp Tyr Asn Ala Gly Leu				
	20	25		30	
15	Leu Ser Tyr Tyr Thr Ser Lys Asp Lys Met Met Arg Gly Ser Arg Arg	35	40	45	
	Gly Cys Val Arg Leu Arg Gly Ala Val Ile Gly Ile Asp Asp Glu Asp	50	55	60	
20	Asp Ser Thr Phe Thr Ile Thr Val Asp Gln Lys Thr Phe His Phe Gln	65	70	75	80
	Ala Arg Asp Ala Asp Glu Arg Glu Lys Trp Ile His Ala Leu Glu Glu	85	90	95	
25	Thr Ile Leu Arg His Thr Leu Gln Leu Gln Gly Leu Asp Ser Gly Phe	100	105	110	
30	Ile Pro Ser Val Gln Asp Phe Asp Lys Lys Leu Thr Glu Ala Asp Ala	115	120	125	
	Tyr Leu Gln Ile Leu Ile Glu Gln Leu Lys Leu Phe Asp Asp Lys Leu	130	135	140	
35	Gln Asn Cys Lys Asp Asp Glu Gln Arg Lys Lys Val Glu Thr Leu Lys	145	150	155	160
40	Asp Thr Thr Asn Ser Met Val Glu Ser Ile Lys His Cys Ile Val Leu	165	170	175	
	Leu Gln Ile Ala Lys Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln	180	185	190	
45	Pro Ser Pro Leu Glu Pro Val Ile Ser Thr Met Pro Ser Gln Thr Ala	195	200	205	
	Leu Pro Pro Glu Pro Ala Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser	210	215	220	
50	Ser Leu Pro Val Gly Pro Val Leu Ala Thr Leu Gly His His Gln Thr	225	230	235	240
55	Pro Thr Pro Asn Ser Thr Gly Ser Gly Asn Ser Pro Pro Ser Ser Ser	245	250	255	
	Leu Thr Pro Pro Ser His Val Asn Leu Ser Pro Asn Thr Val Pro Glu	260	265	270	
60	Phe Ser Tyr Ser Ser Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe	275	280	285	

His Gln Ser Gly Ser Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser
 290 295 300
 Ala Ser Val Leu Thr His Ser Ser Ser Gly Asn Ser Leu Lys Arg Pro
 5 305 310 315 320
 Asp Thr Thr Glu Ser Leu Asn Ser Ser Met Ser Asn Gly Thr Ser Asp
 325 330 335
 10 Ala Asp Leu Phe Asp Ser His Asp Asp Arg Asp Asp Gly Glu Ala
 340 345 350
 Gly Ser Val Glu Glu His Lys Ser Val Ile Met His Leu Leu Ser Gln
 355 360 365
 15 Val Arg Leu Gly Met Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile
 370 375 380
 Leu Glu Arg Arg Ser Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His
 20 385 390 395 400
 Pro Asp Leu Phe Val Ser Ile Ser Asp Gln Lys Asp Pro Arg Asp Arg
 405 410 415
 25 Met Val Gln Val Val Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg
 420 425 430
 Arg Gly Ser Val Ala Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile
 435 440 445
 30 Phe Gln Cys His Trp Thr Leu Pro Asn Asp Thr Glu Glu Asn Ala Glu
 450 455 460
 Leu Val Ser Glu Gly Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr
 35 465 470 475 480
 Phe Val Ala Glu Gln Val Ser His His Pro Pro Ile Ser Ala Phe Tyr
 485 490 495
 40 Ala Glu Cys Phe Asn Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr
 500 505 510
 Lys Ser Lys Phe Leu Gly Met Ser Ile Gly Val His Asn Ile Gly Gln
 515 520 525
 45 Gly Cys Val Ser Cys Leu Glu Tyr Asp Glu His Tyr Ile Leu Thr Phe
 530 535 540
 50 Pro Asn Gly Tyr Gly Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu
 545 550 555 560
 Gly Gly Glu Cys Asn Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn
 565 570 575
 55 Ile Val Phe His Thr Lys Pro Phe Tyr Gly Gly Lys Lys His Arg Ile
 580 585 590
 Thr Ala Glu Ile Phe Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile
 595 600 605
 60 Glu Gly Glu Trp Asn Gly Ile Met Tyr Ala Lys Tyr Ala Thr Gly Glu
 610 615 620

Asn Thr Val Phe Val Asp Thr Lys Lys Leu Pro Ile Ile Lys Lys Lys
625 630 635 640

5 Val Arg Lys Leu Glu Asp Gln Asn Glu Tyr Glu Ser Arg Ser Leu Trp
645 650 655

Lys Asp Val Thr Phe Asn Leu Lys Ile Arg Asp Ile Asp Ala Ala Thr
660 665 670

10 Glu Ala Lys His Arg Leu Glu Glu Arg Gln Arg Ala Glu Ala Arg Glu
675 680 685

15 Arg Lys Glu Lys Glu Ile Gln Trp Glu Thr Arg Leu Phe His Glu Asp
690 695 700

Gly Glu Cys Trp Val Tyr Asp Glu Pro Leu Leu Lys Arg Leu Gly Ala
705 710 715 720

20 Val Lys His

<210> 3
 <211> 2534
 <212> DNA
 <213> ARTIFICIAL SEQUENCE
 5
 <400> 3
 gggcccttcc cctgagacgg cggccggccg ccgcgaatgg ctctcctgtc ggccgcttgc 60
 ggagggtttgg attcaggatt catccccagt gtccaagact ttgataagaa acttaccgag 120
 10 gctgacgcgt acctgcagat cttgatagaa caattaaagc ttttgatga caagcttcaa 180
 aattgtaaag atgatgaaca gagaaagaaa gttgaaactc tcaaagacac aacaaatagc 240
 15 atggtagaat caattaaaca ctgcattgtg ttgctacaga ttgctaaaag tactattaat 300
 cctgttagatg caatatacca gcctagtcgg ttgaaacctg tgatcagcac aatgccttcc 360
 20 cagactgcct tacctccaga acccgctcag ttgtgttaat cagagcagcg tccatcttcc 420
 ttacctgttg gacctgtgtt agctacatttgg gacatcatc agactccaa accaaatagt 480
 acaggcagtg ggaactcacc acctaggcagc agtctgactc ctcccagcca tgtcaacttg 540
 25 tctccaaata cagtcccaga gttctttac tctagcagtg aagatgagtt ctatgatgct 600
 gatgaattcc atcaaagtgg ctgcgtccca aagcgcttaa tagatttttc tggatctgcc 660
 30 tcagtcttgc cacacagcag ctccggaaat agctaaaaac gcccgatac cacagagtct 720
 ctgaattccct ccatgtccaa tggcacaagc gatgctgatc ttttgactc acatgacgac 780
 agagatgatg atggggaggc tgggtcagtg gaggagcaca agagcgttat catgcaccc 840
 35 ttatcacaag tcaggctggg gatggaccc acaaaggtag ttcttccaaac gtttattctc 900
 gagagaagat ctctgttaga aatgtatgca gacttttcg cacatccaga cctgttcgtg 960
 40 agcatttagtg atcagaagga tcccagggtt cgaatggtc aggttgtgaa atggtacctc 1020
 tcggccttcc atgcaggaag gagaggatcg gtggccaaaa agccgtacaa tcctattttg 1080
 ggtgagatct ttcaagtgtca ctggacgttg ccgaatgata ctgaagagaa cgccagagctc 1140
 45 gtttcagaag ggccggttcc ctgggtttct aagaacagtg taacatttg ggctgagcaa 1200
 gtttcccacc atccgcccattt ttcagcctt tatgctgagt gttttacaaa gaagatacaa 1260
 50 ttcaatgctc atatctggac taaatcaaaa ttccctggga tgtcaattgg ggtacacaac 1320
 ataggtcagg gctgtgtctc gtgtctggag tacgtgagc actacatccct cacgttccccc 1380
 aatggctatg gaaggtctat cctgacagtg ccctgggtgg aattgggagg agaatgcaat 1440
 55 atcaactgct ccaaaacggg ttacagcgca aacatcgct tccacactaa gccttcttat 1500
 gggggcaaga agcacagaat tactgcagag atttttctc cgaatgacaa gaaatccttc 1560
 tgctcaatttgc aaggggaaatg gaatggtac atgtatgcaa aatacgcaac aggggaaaac 1620
 60 actgtctttg tagacacccaa gaaattgcct ataatcaaga aaaaggtgag gaagttggaa 1680

	gatcagaatg agtatgagtc ccgcagcctt tggaggatg tcactttcaa tttaaaaatc	1740
	agagacattg atgcagcaac ggaagcaaag cacagacttg aagaaagaca aagagcagaa	1800
5	gccc gagaaa ggaaggagaa ggaaattcag tggagacga ggctttca cgaggatggc	1860
	aatgctggg tttacgtga gccttactg aagcgtctt gtgctgtgaa gcattaggcc	1920
	gacaaccgag tccacacctg gtgaccaggg cagtaggcgt aattaagcaa caatcgatct	1980
10	tccttcagga gagcttgtca cttccttctt aacgcagtgg ttccttatctc agggatactg	2040
	gacttgcga cacagatgaa caattaaagt ggaaaccgct tccctttct cctctgtggc	2100
15	agttacaatt ttgacttcag gcctgagaaa aacttcagg ttcgaaacat gacatcttctt	2160
	cctttccag atccccatgct ttgaaaaata tttatagaca gttccaggc tcagcttcct	2220
20	gtcctctagt tctgctgttc gggataaaaa tctttatctc cagttcatat aatcttgagt	2280
	tttagataka cacacatgctg taacagctga cagttttca caagtacacc cacctgtaaa	2340
	tactgtakcc tcagttttaga aaatttagtgc atgtatgaaa atcaagtgtt aggaaatttc	2400
25	atggttcac ctataaccctt tattttagaa ttgaactatg attagattgt atctaaacct	2460
	gaagtataat tatatgcagt gcttcttaag gcttcataaaa ataattttcc aaccttttta	2520
30	aaaaaaaaaaa aaaa	2534

<210> 4
 <211> 626
 <212> PRT
 <213> ARTIFICIAL SEQUENCE
 5
 <400> 4

	Met Ala Leu Leu Leu Ala Ala Cys Gly Gly	Leu Asp Ser Gly Phe Ile		
1	5	10	15	
10	Pro Ser Val Gln Asp Phe Asp Lys Lys	Leu Thr Glu Ala Asp Ala Tyr		
	20	25	30	
15	Leu Gln Ile Leu Ile Glu Gln Leu Lys Leu Phe Asp Asp Lys Leu Gln			
	35	40	45	
20	Asn Cys Lys Asp Asp Glu Gln Arg Lys Lys Val Glu Thr Leu Lys Asp			
	50	55	60	
25	Thr Thr Asn Ser Met Val Glu Ser Ile Lys His Cys Ile Val Leu Leu			
	65	70	75	80
	Gln Ile Ala Lys Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln Pro			
	85	90	95	
25	Ser Pro Leu Glu Pro Val Ile Ser Thr Met Pro Ser Gln Thr Ala Leu			
	100	105	110	
30	Pro Pro Glu Pro Ala Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser Ser			
	115	120	125	
	Leu Pro Val Gly Pro Val Leu Ala Thr Leu Gly His His Gln Thr Pro			
	130	135	140	
35	Thr Pro Asn Ser Thr Gly Ser Gly Asn Ser Pro Pro Ser Ser Ser Leu			
	145	150	155	160
	Thr Pro Pro Ser His Val Asn Leu Ser Pro Asn Thr Val Pro Glu Phe			
	165	170	175	
40	Ser Tyr Ser Ser Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe His			
	180	185	190	
45	Gln Ser Gly Ser Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser Ala			
	195	200	205	
	Ser Val Leu Thr His Ser Ser Gly Asn Ser Leu Lys Arg Pro Asp			
	210	215	220	
50	Thr Thr Glu Ser Leu Asn Ser Ser Met Ser Asn Gly Thr Ser Asp Ala			
	225	230	235	240
	Asp Leu Phe Asp Ser His Asp Asp Arg Asp Asp Gly Glu Ala Gly			
	245	250	255	
55	Ser Val Glu Glu His Lys Ser Val Ile Met His Leu Leu Ser Gln Val			
	260	265	270	
60	Arg Leu Gly Met Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile Leu			
	275	280	285	
	Glu Arg Arg Ser Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His Pro			

	290	295	300
	Asp Leu Phe Val Ser Ile Ser Asp Gln Lys Asp Pro Arg Asp Arg Met		
5	305 310	315	320
	Val Gln Val Val Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg Arg		
	325	330	335
10	Gly Ser Val Ala Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile Phe		
	340	345	350
	Gln Cys His Trp Thr Leu Pro Asn Asp Thr Glu Glu Asn Ala Glu Leu		
	355	360	365
15	Val Ser Glu Gly Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr Phe		
	370	375	380
	Val Ala Glu Gln Val Ser His His Pro Pro Ile Ser Ala Phe Tyr Ala		
20	385 390	395	400
	Glu Cys Phe Asn Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr Lys		
	405	410	415
25	Ser Lys Phe Leu Gly Met Ser Ile Gly Val His Asn Ile Gly Gln Gly		
	420	425	430
	Cys Val Ser Cys Leu Glu Tyr Asp Glu His Tyr Ile Leu Thr Phe Pro		
	435	440	445
30	Asn Gly Tyr Gly Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu Gly		
	450	455	460
	Gly Glu Cys Asn Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn Ile		
35	465 470	475	480
	Val Phe His Thr Lys Pro Phe Tyr Gly Gly Lys Lys His Arg Ile Thr		
	485	490	495
40	Ala Glu Ile Phe Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile Glu		
	500	505	510
	Gly Glu Trp Asn Gly Ile Met Tyr Ala Lys Tyr Ala Thr Gly Glu Asn		
	515	520	525
45	Thr Val Phe Val Asp Thr Lys Lys Leu Pro Ile Ile Lys Lys Val		
	530	535	540
	Arg Lys Leu Glu Asp Gln Asn Glu Tyr Glu Ser Arg Ser Leu Trp Lys		
50	545 550	555	560
	Asp Val Thr Phe Asn Leu Lys Ile Arg Asp Ile Asp Ala Ala Thr Glu		
	565	570	575
	Ala Lys His Arg Leu Glu Glu Arg Gln Arg Ala Glu Ala Arg Glu Arg		
55	580	585	590
	Lys Glu Lys Glu Ile Gln Trp Glu Thr Arg Leu Phe His Glu Asp Gly		
	595	600	605
60	Glu Cys Trp Val Tyr Asp Glu Pro Leu Leu Lys Arg Leu Gly Ala Val		
	610	615	620

Lys His
625

5	<210>	5					
	<211>	2840					
	<212>	DNA					
	<213>	Homo sapiens					
10	<400>	5					
	tcccaagatg	gcgtccatca	tggaagggcc	gctgagcaaa	tggactaacg	tcatgaaggg	60
15	ctggcagtac	cgttggttcg	tgctggacta	caatgcagga	ctgctctcct	actacacgtc	120
	caaggacaaa	atgatgagag	gctctcgac	aggatgttt	agactcagag	gagctgttat	180
	tggatagac	gatgaggacg	acagcacctt	cacaataact	gttgcata	aaaccttcca	240
20	tttccaggcc	cgtgatgctg	atgagcgaga	gaagtggatc	catgccttag	aagaaacaat	300
	tcttcgacat	actctccagc	ttcaaggttt	ggattcagga	tttgcata	gtgtccaa	360
25	ttttgataag	aaacttacag	aagctgatgc	ttacctacaa	atcttgcattt	aacaattaaa	420
	gcttttgc	gacaagcttc	aaaactgcaa	agaagatgaa	cagagaaaga	aaattgaaac	480
	tctcaaagag	acaacaaata	gcatggtaga	atcaattaaa	cactgcattt	tgttgcgtca	540
30	gattgccaaa	agtactatta	atcccgtaga	tgcaatata	caacctagtc	ctttggaaacc	600
	tgtgatcagc	acaatgcctt	cccagactgt	gttacctcca	gaacctgttc	agttgtgtaa	660
35	gtcagagcag	cgtccatctt	ccctaccagt	tggacctgtt	ttggotacct	tggacatca	720
	ttagactcct	acaccaaata	gtacaggcag	tggccattca	ccaccgagta	gcagtctcac	780
	ttctccaagc	cacgtgaact	tgttccaaa	tacagtccca	gagttcttctt	actccagcag	840
40	tgaagatgaa	ttttatgatg	ctgatgaatt	ccatcaaagt	ggctcatccc	caaagcgctt	900
	aatagattct	tctggatctg	cctcagtcct	gacacacagc	agctcgggaa	atagtctaaa	960
45	acgcccagat	accacagaat	cacttaattt	ttccctgtcc	aatggacaaa	gtgatgctga	1020
	cctgtttgc	tcacatgatg	acagagatga	tcatgcggag	gcagggtctg	tggaggagca	1080
	caagagcgtt	atcatgcattc	tcttgcgtca	ggtagactt	ggaatggatc	ttactaagg	1140
50	agttcttcca	acgtttattt	ttgaaagaag	atctctttt	gaaatgtatg	cagacttttt	1200
	tgcacatccg	gacctgtttt	tgagcattag	tgaccagaag	gatcccaagg	atcgaatgg	1260
55	tcaggttgtt	aatggtacc	tctcagcctt	tcatgcggga	aggaaaggat	cagttgcca	1320
	aaagccatac	aatcccattt	tggcgagat	ttttcagttt	cattggacat	taccaaata	1380
	tactgaagag	aacacagaac	tagttcaga	aggaccagg	ccctgggttt	ccaaaaacag	1440
60	tgtaacattt	gtggctgagc	aggtttccca	tcatccaccc	atttcagcct	tttatgcgt	1500
	gtgttttaac	aagaagatac	aattcaatgc	tcatatctgg	accaaata	aattccttgg	1560

	gatgtcaatt	ggggtgtcaca	acatagggca	gggctgtgtc	tcatgtctag	actatgtga	1620
5	acattacatt	ctcacattcc	ccaatggcta	tggaagggtct	atcctcacag	tgcctgggt	1680
	ggaatttagga	ggagaatgca	atattaattt	ttccaaaaca	ggctatacg	caaatatcat	1740
	cttccacact	aaacccttct	atggggcaa	gaagcacaga	attactgccg	agatttttc	1800
10	tccaaatgac	aagaagtctt	tttgctcaat	tgaagggaa	tggaatggtg	tgtgtatgc	1860
	aaaatatgca	acagggaaaa	atacagtctt	tgtagatacc	aagaagttgc	ctataatcaa	1920
15	gaagaaagtg	aggaagttgg	aagatcagaa	cgagtatgaa	tcccgcagcc	tttggaaagga	1980
	tgtcactttc	aacttaaaaa	tcagagacat	tgtgcagca	actgaagcaa	agcacaggct	2040
	tgaagaaaga	caaagagcag	aagcccgaga	aaggaaggag	aaggaaattc	agtgggagac	2100
20	aaggttat	catgaagatg	gagaatgctg	gttttatgt	gaaccattac	tgaaacgtct	2160
	tggtgctgcc	aagcattagg	ttggaagatg	caaagttt	acctgatgt	cagggcagta	2220
25	ggcataattc	agcaacaaac	aatttccctt	tggagaaac	ctgttcattc	caatcttcta	2280
	attacagtgg	ttccttatctc	aggatactg	gactttctga	cgcagatgaa	caattaaggg	2340
	gaaaagcttc	cctttccct	ctgtggcagt	tacgattttg	acttcagtcc	tgagaaaaac	2400
30	ttcaggtttt	gaaaatcaga	tgtgtcttc	tcctttcca	aacaccacac	gttgaaagca	2460
	tttataaatac	caagtctgaa	actctgcgct	ctagtaactgc	tgttaagata	cacaacttgt	2520
35	ttcttagttc	atataatctc	gggatacaca	cacacacaca	tatataatata	cacacacata	2580
	cgtatacaca	cacatacata	tataaatata	cctgatgcc	gatttttc	ataaatattc	2640
	tgcctactgt	aaatatgggt	tcctctgagt	tgttttagaa	aattagcgca	atgttataaa	2700
40	atcaagtgtt	aggaaatttc	atggtcttac	ctacaataac	ttttattttg	gaattgaact	2760
	attattaaat	tgtatcta	cctggattac	agtttaatta	attattctt	gtgcttaagg	2820
	tttcataaaag	taatttttcc					2840
45							
	<210>	6					
	<211>	723					
	<212>	PRT					
50	<213>	Homo sapiens					
	<400>	6					
55	Met Ala Ser Ile Met Glu Gly Pro Leu Ser Lys Trp Thr Asn Val Met						
	1	5		10		15	
60	Lys Gly Trp Gln Tyr Arg Trp Phe Val Leu Asp Tyr Asn Ala Gly Leu						
	20	25		30			

Leu Ser Tyr Tyr Thr Ser Lys Asp Lys Met Met Arg Gly Ser Arg Arg
 35 40 45

5 Gly Cys Val Arg Leu Arg Gly Ala Val Ile Gly Ile Asp Asp Glu Asp
 50 55 60

10 Asp Ser Thr Phe Thr Ile Thr Val Asp Gln Lys Thr Phe His Phe Gln
 65 70 75 80

15 Ala Arg Asp Ala Asp Glu Arg Glu Lys Trp Ile His Ala Leu Glu Glu
 85 90 95

Thr Ile Leu Arg His Thr Leu Gln Leu Gln Gly Leu Asp Ser Gly Phe
 100 105 110

20 Val Pro Ser Val Gln Asp Phe Asp Lys Lys Leu Thr Glu Ala Asp Ala
 115 120 125

25 Tyr Leu Gln Ile Leu Ile Glu Gln Leu Lys Leu Phe Asp Asp Lys Leu
 130 135 140

30 Gln Asn Cys Lys Glu Asp Glu Gln Arg Lys Lys Ile Glu Thr Leu Lys
 145 150 155 160

35 Glu Thr Thr Asn Ser Met Val Glu Ser Ile Lys His Cys Ile Val Leu
 165 170 175

Leu Gln Ile Ala Lys Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln
 180 185 190

40 Pro Ser Pro Leu Glu Pro Val Ile Ser Thr Met Pro Ser Gln Thr Val
 195 200 205

45 Leu Pro Pro Glu Pro Val Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser
 210 215 220

50 Ser Leu Pro Val Gly Pro Val Leu Ala Thr Leu Gly His His Gln Thr
 225 230 235 240

55 Pro Thr Pro Asn Ser Thr Gly Ser Gly His Ser Pro Pro Ser Ser Ser
 245 250 255

Leu Thr Ser Pro Ser His Val Asn Leu Ser Pro Asn Thr Val Pro Glu
 260 265 270

60 Phe Ser Tyr Ser Ser Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe
 275 280 285

His Gln Ser Gly Ser Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser
290 295 300
5

Ala Ser Val Leu Thr His Ser Ser Ser Gly Asn Ser Leu Lys Arg Pro
305 310 315 320
10

Asp Thr Thr Glu Ser Leu Asn Ser Ser Leu Ser Asn Gly Thr Ser Asp
325 330 335

15 Ala Asp Leu Phe Asp Ser His Asp Asp Arg Asp Asp Ala Glu Ala
340 345 350

20 Gly Ser Val Glu Glu His Lys Ser Val Ile Met His Leu Leu Ser Gln
355 360 365
25 Val Arg Leu Gly Met Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile
370 375 380
30 Leu Glu Arg Arg Ser Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His
385 390 395 400
35 Pro Asp Leu Phe Val Ser Ile Ser Asp Gln Lys Asp Pro Lys Asp Arg
405 410 415
40 Met Val Gln Val Val Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg
420 425 430
45 Lys Gly Ser Val Ala Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile
435 440 445
Phe Gln Cys His Trp Thr Leu Pro Asn Asp Thr Glu Glu Asn Thr Glu
450 455 460
465 Leu Val Ser Glu Gly Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr
470 475 480
50 Phe Val Ala Glu Gln Val Ser His His Pro Pro Ile Ser Ala Phe Tyr
485 490 495
55 Ala Glu Cys Phe Asn Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr
500 505 510
60 Lys Ser Lys Phe Leu Gly Met Ser Ile Gly Val His Asn Ile Gly Gln
515 520 525

Gly Cys Val Ser Cys Leu Asp Tyr Asp Glu His Tyr Ile Leu Thr Phe
530 535 540

5 Pro Asn Gly Tyr Gly Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu
545 550 555 560

10 Gly Gly Glu Cys Asn Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn
565 570 575

15 Ile Ile Phe His Thr Lys Pro Phe Tyr Gly Gly Lys Lys His Arg Ile
580 585 590

20 Thr Ala Glu Ile Phe Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile
595 600 605

25 Glu Gly Glu Trp Asn Gly Val Met Tyr Ala Lys Tyr Ala Thr Gly Glu
610 615 620

30 Asn Thr Val Phe Val Asp Thr Lys Lys Leu Pro Ile Ile Lys Lys Lys
625 630 635 640

35 Val Arg Lys Leu Glu Asp Gln Asn Glu Tyr Glu Ser Arg Ser Leu Trp
645 650 655

40 Lys Asp Val Thr Phe Asn Leu Lys Ile Arg Asp Ile Asp Ala Ala Thr
660 665 670

45 Glu Ala Lys His Arg Leu Glu Glu Arg Gln Arg Ala Glu Ala Arg Glu
675 680 685

50 Arg Lys Glu Lys Glu Ile Gln Trp Glu Thr Arg Leu Phe His Glu Asp
690 695 700

55 Gly Glu Cys Trp Val Tyr Asp Glu Pro Leu Leu Lys Arg Leu Gly Ala
705 710 715 720

55 Ala Lys His

<210> 7
<211> 2457
<212> DNA
<213> Homo sapiens

60 <400> 7

60 cggccctac ccctgagtcc cgggggtccc ggccgccagg ccggagcgcg aatgtcgtgc 60
tcaccctgcc tccttccgc cgccccctgg gctttttgat gacaagcttc aaaactgcaa 120

	agaagatgaa cagagaaaaga aaattgaaac tctcaaagag acaacaata gcatggtaga	180
5	atcaattaaa cactgcattg tggctgctgca gattgccaaa agtactatta atcccgtaga	240
	tgcaatatat caacctagtc ctgggaacc tgtgatcagc acaatgcctt cccagactgt	300
	gttacctcca gaacctgttc agttgttaa gtcagagcag cgtccatctt ccctaccagt	360
10	tggacctgtg ttggctacct tgggacatca tcagactcct acaccaaata gtacaggcag	420
	tggccattca ccaccgagta gcagtctcac ttctccaagc cacgtgaact tgtctccaaa	480
15	tacagtcccc gagttctctt actccagcag tgaagatgaa ttttatgatg ctgatgaatt	540
	ccatcaaagt ggctcatccc caaagcgtt aatagattct tctggatctg cctcagtccct	600
	gacacacagc agctcgaaaa atagtctaaa acgcccagat accacagaat cacttaattc	660
20	ttccttgtcc aatggaacaa gtgatgctga cctgtttgat tcacatgatg acagagatga	720
	tgatgcggag gcagggctcg tggaggagca caagagcgtt atcatgcattc tcttgcgca	780
25	ggttagactt ggaatggatc ttactaaggt agttcttcca acgtttattc ttgaaagaag	840
	atctctttta gaaatgtatg cagactttt tgcacatccg gacctgtttg tgaggcattag	900
	tgaccagaag gatcccaagg atcgaatggt tcaggttggaa atatggtacc tctcagccctt	960
30	tcatgcggga aggaaaggat cagttccaa aaagccatac aatcccattt tggcgagat	1020
	ttttcagtgt cattggacat taccaaatga tactgaagag aacacagaac tagttcaga	1080
35	aggaccagtt ccctgggttt ccaaaaacag tgtaacattt gtggctgagc aggtttccca	1140
	tcatccaccc atttcagccct tttatgctga gtgttttaac aagaagatac aattcaatgc	1200
	tcatatctgg accaaatcaa aattccttgg gatgtcaattt ggggtgcaca acataggcata	1260
40	gggtgtgtc tcatgtctag actatgatga acattacatt ctcacattcc ccaatggcta	1320
	tggaaaggct atcctcacag tgccctgggt ggaatttagga ggagaatgca atattaattt	1380
45	ttccaaaaca ggctacagtg caaatatcat cttccacact aaacccttct atgggggcaaa	1440
	gaagcacaga attactgccg agattttttc tccaaatgac aagaagtctt ttgtcaat	1500
	tgaaggggaa tggaatggtg tgatgtatgc aaaatatgca acagggaaa atacagtctt	1560
50	tgtagatacc aagaagttgc ctataatcaa gaagaaagtg aggaagttgg aagatcagaa	1620
	cgtatgaa tcccgcagcc tttgaaagga tgcactttc aactttaaaaa tcagagacat	1680
55	tgtatgcagca actgaagcaa agcacaggct tgaagaaaga caaagagcag aagcccgaga	1740
	aaggaaggag aaggaaattc agtggagac aaggttattt catgaagatg gagaatgctg	1800
	ggtttatgat gaaccattac tggaaacgtct tgggtgctgcc aagcattagg ttgaaagatg	1860
60	caaagtttat acctgtatgat cagggcagta ggcataattc agcaacaaac aatcttcctt	1920
	tggagaaac ctgttcattc caatcttcta attacagtgg ttcctatctc agggatactg	1980

	gactttctga cgccagatgaa caattaagg gaaaagcttc cctttccct ctgtggcagt	2040
5	tacgattttg acttcagtcc tgagaaaaac ttccagggttt gaaaatcaga tgcgtcttc	2100
	tcctttcca aacaccacac gttgaaagca ttataaaatc caagtcgaa actctgcgct	2160
	ctagtactgc tgttaagata cacaacttgt tcttagtgc atataatctc gggatacaca	2220
10	cacacacaca catatatata cacacacata cgtatacaca cacatacata tatataaata	2280
	tacctgatgc cagattttt tcataaatat tctgcctact gtaaatatgg gttcctctga	2340
15	gttgtttag aaaattagcg caatgttata aaatcaagtg ttaggaaatt tcatggtctt	2400
	acctacaata acttttattt tggaattgaa ctattattaa attgtatcta atcctgg	2457
20	<210> 8	
	<211> 558	
	<212> PRT	
	<213> Homo sapiens	
25	<400> 8	
	Met Val Glu Ser Ile Lys His Cys Ile Val Leu Leu Gln Ile Ala Lys	
	1 5 10 15	
30	Ser Thr Ile Asn Pro Val Asp Ala Ile Tyr Gln Pro Ser Pro Leu Glu	
	20 25 30	
35	Pro Val Ile Ser Thr Met Pro Ser Gln Thr Val Leu Pro Pro Glu Pro	
	35 40 45	
40	Val Gln Leu Cys Lys Ser Glu Gln Arg Pro Ser Ser Leu Pro Val Gly	
	50 55 60	
	Pro Val Leu Ala Thr Leu Gly His His Gln Thr Pro Thr Pro Asn Ser	
	65 70 75 80	
45	Thr Gly Ser Gly His Ser Pro Pro Ser Ser Ser Leu Thr Ser Pro Ser	
	85 90 95	
50	His Val Asn Leu Ser Pro Asn Thr Val Pro Glu Phe Ser Tyr Ser Ser	
	100 105 110	
55	Ser Glu Asp Glu Phe Tyr Asp Ala Asp Glu Phe His Gln Ser Gly Ser	
	115 120 125	
60	Ser Pro Lys Arg Leu Ile Asp Ser Ser Gly Ser Ala Ser Val Leu Thr	
	130 135 140	

His Ser Ser Ser Gly Asn Ser Leu Lys Arg Pro Asp Thr Thr Glu Ser
145 150 155 160

5 Leu Asn Ser Ser Leu Ser Asn Gly Thr Ser Asp Ala Asp Leu Phe Asp
165 170 175

10 Ser His Asp Asp Arg Asp Asp Ala Glu Ala Gly Ser Val Glu Glu
180 185 190

15 His Lys Ser Val Ile Met His Leu Leu Ser Gln Val Arg Leu Gly Met
195 200 205

20 Asp Leu Thr Lys Val Val Leu Pro Thr Phe Ile Leu Glu Arg Arg Ser
210 215 220

Leu Leu Glu Met Tyr Ala Asp Phe Phe Ala His Pro Asp Leu Phe Val
225 230 235 240

25 Ser Ile Ser Asp Gln Lys Asp Pro Lys Asp Arg Met Val Gln Val Val
245 250 255

30 Lys Trp Tyr Leu Ser Ala Phe His Ala Gly Arg Lys Gly Ser Val Ala
260 265 270

35 Lys Lys Pro Tyr Asn Pro Ile Leu Gly Glu Ile Phe Gln Cys His Trp
275 280 285

40 Thr Leu Pro Asn Asp Thr Glu Glu Asn Thr Glu Leu Val Ser Glu Gly
290 295 300

Pro Val Pro Trp Val Ser Lys Asn Ser Val Thr Phe Val Ala Glu Gln
305 310 315 320

45 Val Ser His His Pro Pro Ile Ser Ala Phe Tyr Ala Glu Cys Phe Asn
325 330 335

50 Lys Lys Ile Gln Phe Asn Ala His Ile Trp Thr Lys Ser Lys Phe Leu
340 345 350

55 Gly Met Ser Ile Gly Val His Asn Ile Gly Gln Gly Cys Val Ser Cys
355 360 365

60 Leu Asp Tyr Asp Glu His Tyr Ile Leu Thr Phe Pro Asn Gly Tyr Gly
370 375 380

Arg Ser Ile Leu Thr Val Pro Trp Val Glu Leu Gly Gly Glu Cys Asn

18

385 390 395 400

5 Ile Asn Cys Ser Lys Thr Gly Tyr Ser Ala Asn Ile Ile Phe His Thr
 405 410 415

10 Lys Pro Phe Tyr Gly Gly Lys His Arg Ile Thr Ala Glu Ile Phe
 420 425 430

15 Ser Pro Asn Asp Lys Lys Ser Phe Cys Ser Ile Glu Gly Glu Trp Asn
 435 440 445

20 Gly Val Met Tyr Ala Lys Tyr Ala Thr Gly Glu Asn Thr Val Phe Val
 450 455 460

25 Asp Thr Lys Lys Leu Pro Ile Ile Lys Lys Lys Val Arg Lys Leu Glu
 465 470 480

30 Asp Gln Asn Glu Tyr Glu Ser Arg Ser Leu Trp Lys Asp Val Thr Phe
 485 490 495

35 Asn Leu Lys Ile Arg Asp Ile Asp Ala Ala Thr Glu Ala Lys His Arg
 500 505 510

40 Leu Glu Glu Arg Gln Arg Ala Glu Ala Arg Glu Arg Lys Glu Lys Glu
 515 520 525

45 Ile Gln Trp Glu Thr Arg Leu Phe His Glu Asp Gly Glu Cys Trp Val
 530 535 540

50 Tyr Asp Glu Pro Leu Leu Lys Arg Leu Gly Ala Ala Lys His
 545 550 555

55 <210> 9

55 <211> 21

55 <212> DNA

55 <213> Artificial

60 <400> 9

60 ccaaagctcta atacgactca c

21

55 <210> 10

55 <211> 20

55 <212> DNA

55 <213> Artificial

60 <400> 10

60 ctcagccaca aatgttacac

20

<210> 11
<211> 32
<212> DNA
<213> Artificial
5
<400> 11
ctagcttagca ccatggcgtc catcgtggaa gg 32

10 <210> 12
<211> 35
<212> DNA
<213> Artificial

15 <400> 12
ataagaatgc ggccgcgagg agaaaaggga agcgg 35

20 <210> 13
<211> 35
<212> DNA
<213> Artificial

<400> 13
25 ctagcttagca ccatggctct cctgctggcc gcttg 35

30 <210> 14
<211> 29
<212> DNA
<213> Artificial

<400> 14
cccgggcatg ctacacagca ccaagacgc 29
35